NO310473B1 - Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid - Google Patents

Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid Download PDF

Info

Publication number: NO310473B1
Authority: NO; Norway
Prior art keywords: immunoglobulin; human; amino acid; cdr; humanized
Prior art date: 1988-12-28

Application number

NO19912385A

Other languages

English (en)

Norwegian (no)

Other versions

NO912385L (no

NO912385D0 (no

Inventor

Cary L Queen

Harold Edwin Selick

Original Assignee

Protein Design Labs Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-28

Filing date

1991-06-19

Publication date

2001-07-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO310473(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-06-19 Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc

1991-06-19 Publication of NO912385L publication Critical patent/NO912385L/no

1991-06-19 Publication of NO912385D0 publication Critical patent/NO912385D0/no

2001-07-09 Publication of NO310473B1 publication Critical patent/NO310473B1/no

Links

108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 133
102000018358 immunoglobulin Human genes 0.000 title claims abstract description 133
238000000034 method Methods 0.000 title claims description 40
108091033319 polynucleotide Proteins 0.000 title claims description 14
102000040430 polynucleotide Human genes 0.000 title claims description 14
239000002157 polynucleotide Substances 0.000 title claims description 14
238000002360 preparation method Methods 0.000 title description 3
150000001413 amino acids Chemical class 0.000 claims abstract description 93
108090000623 proteins and genes Proteins 0.000 claims abstract description 61
102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 36
230000027455 binding Effects 0.000 claims abstract description 32
102000004169 proteins and genes Human genes 0.000 claims abstract description 31
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 22
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 13
102000000588 Interleukin-2 Human genes 0.000 claims abstract description 13
102000055277 human IL2 Human genes 0.000 claims abstract description 3
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 62
125000003275 alpha amino acid group Chemical group 0.000 claims description 24
239000000427 antigen Substances 0.000 claims description 19
108091007433 antigens Proteins 0.000 claims description 19
102000036639 antigens Human genes 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 18
238000006467 substitution reaction Methods 0.000 claims description 10
230000003993 interaction Effects 0.000 claims description 8
125000000539 amino acid group Chemical group 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 4
108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
238000002955 isolation Methods 0.000 claims description 3
239000006143 cell culture medium Substances 0.000 claims description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 abstract description 18
102000005962 receptors Human genes 0.000 abstract description 5
108020003175 receptors Proteins 0.000 abstract description 5
150000007523 nucleic acids Chemical class 0.000 abstract description 3
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
241001529936 Murinae Species 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 68
229940072221 immunoglobulins Drugs 0.000 description 29
210000001744 T-lymphocyte Anatomy 0.000 description 26
108091034117 Oligonucleotide Proteins 0.000 description 23
239000000203 mixture Substances 0.000 description 22
241000699666 Mus <mouse, genus> Species 0.000 description 20
239000000370 acceptor Substances 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
239000013612 plasmid Substances 0.000 description 16
201000010099 disease Diseases 0.000 description 14
239000012634 fragment Substances 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 12
239000002773 nucleotide Substances 0.000 description 12
125000003729 nucleotide group Chemical group 0.000 description 12
238000011282 treatment Methods 0.000 description 12
238000010561 standard procedure Methods 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
239000013598 vector Substances 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
239000002596 immunotoxin Substances 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
230000002637 immunotoxin Effects 0.000 description 7
229940051026 immunotoxin Drugs 0.000 description 7
231100000608 immunotoxin Toxicity 0.000 description 7
239000000126 substance Substances 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000002254 cytotoxic agent Substances 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
239000012636 effector Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108700005091 Immunoglobulin Genes Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000499 gel Substances 0.000 description 5
108090001008 Avidin Proteins 0.000 description 4
241000283707 Capra Species 0.000 description 4
108010004729 Phycoerythrin Proteins 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
229940126619 mouse monoclonal antibody Drugs 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108010039491 Ricin Proteins 0.000 description 3
238000000137 annealing Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000011651 chromium Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000036541 health Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000157426 Pernis Species 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241001474728 Satyrodes eurydice Species 0.000 description 1
241000607720 Serratia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
-1 etc. Substances 0.000 description 1
235000019000 fluorine Nutrition 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940002004 the magic bullet Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO19912385A 1988-12-28 1991-06-19 Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid NO310473B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29097588A	1988-12-28	1988-12-28
US31025289A	1989-02-13	1989-02-13
PCT/US1989/005857 WO1990007861A1 (en)	1988-12-28	1989-12-28	CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

Publications (3)

Publication Number	Publication Date
NO912385L NO912385L (no)	1991-06-19
NO912385D0 NO912385D0 (no)	1991-06-19
NO310473B1 true NO310473B1 (no)	2001-07-09

Family

ID=26966505

Family Applications (9)

Application Number	Title	Priority Date	Filing Date
NO19912385A NO310473B1 (no)	1988-12-28	1991-06-19	Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid
NO2001025C NO2001025I2 (no)	1988-12-28	2001-12-17	Palivizumab
NO2001024C NO2001024I1 (no)	1988-12-28	2001-12-17	Trastuzumab eller farmasøytiske akseptable salter derav
NO2001026C NO2001026I2 (no)	1988-12-28	2001-12-17	Daclizumab
NO2005005C NO2005005I2 (no)	1988-12-28	2005-02-18	Bevacizumab eller farmasoeytisk akseptable salter derav
NO2005026C NO2005026I2 (no)	1988-12-28	2005-12-07	Omalizumab eller farmasoeytisk akseptable salter derav
NO2006009C NO2006009I2 (no)	1988-12-28	2006-08-07	Natalizumab eller farmasoytisk akseptable salter derav
NO2007006C NO2007006I2 (no)	1988-12-28	2007-04-18	Ranibizumab eller farmasoytisk akseptable salter derav
NO2009026C NO2009026I1 (no)	1988-12-28	2009-11-12	Certolizumab pegol

Family Applications After (8)

Application Number	Title	Priority Date	Filing Date
NO2001025C NO2001025I2 (no)	1988-12-28	2001-12-17	Palivizumab
NO2001024C NO2001024I1 (no)	1988-12-28	2001-12-17	Trastuzumab eller farmasøytiske akseptable salter derav
NO2001026C NO2001026I2 (no)	1988-12-28	2001-12-17	Daclizumab
NO2005005C NO2005005I2 (no)	1988-12-28	2005-02-18	Bevacizumab eller farmasoeytisk akseptable salter derav
NO2005026C NO2005026I2 (no)	1988-12-28	2005-12-07	Omalizumab eller farmasoeytisk akseptable salter derav
NO2006009C NO2006009I2 (no)	1988-12-28	2006-08-07	Natalizumab eller farmasoytisk akseptable salter derav
NO2007006C NO2007006I2 (no)	1988-12-28	2007-04-18	Ranibizumab eller farmasoytisk akseptable salter derav
NO2009026C NO2009026I1 (no)	1988-12-28	2009-11-12	Certolizumab pegol

Country Status (31)

Country	Link
EP (6)	EP0682040B1 (ko)
JP (6)	JP2828340B2 (ko)
KR (1)	KR0178385B1 (ko)
CN (1)	CN1057013C (ko)
AT (2)	ATE133452T1 (ko)
AU (1)	AU647383B2 (ko)
BG (1)	BG61095B2 (ko)
CA (2)	CA2006865C (ko)
CZ (1)	CZ418691A3 (ko)
DD (1)	DD296964A5 (ko)
DE (14)	DE98204240T1 (ko)
DK (2)	DK119191A (ko)
ES (5)	ES2523810T3 (ko)
FI (1)	FI108797B (ko)
FR (1)	FR14C0070I1 (ko)
HR (1)	HRP920500B1 (ko)
HU (1)	HU211174A9 (ko)
IE (1)	IE20000331A1 (ko)
IL (2)	IL162181A (ko)
LU (8)	LU90411I2 (ko)
MC (1)	MC2146A1 (ko)
NL (8)	NL990020I2 (ko)
NO (9)	NO310473B1 (ko)
NZ (2)	NZ231984A (ko)
PT (1)	PT92758B (ko)
RU (1)	RU2126046C1 (ko)
SG (1)	SG78258A1 (ko)
SI (1)	SI8912489B (ko)
WO (1)	WO1990007861A1 (ko)
YU (1)	YU48700B (ko)
ZA (1)	ZA899956B (ko)

Families Citing this family (1058)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800815A (en) *	1903-05-05	1998-09-01	Cytel Corporation	Antibodies to P-selectin and their uses
US5851526A (en) *	1985-04-19	1998-12-22	Ludwig Institute For Cancer Research	Methods of treating colon cancer utilizing tumor-specific antibodies
US5449760A (en) *	1987-12-31	1995-09-12	Tanox Biosystems, Inc.	Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US7247453B1 (en) *	1988-12-30	2007-07-24	Oklahoma Medical Research Foundation	Calcium binding recombinant antibody against protein C
DE3900534A1 (de) *	1989-01-10	1990-07-12	Boehringer Mannheim Gmbh	Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US20030225254A1 (en)	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
CA2064915C (en)	1989-08-07	2001-05-29	Deborah A. Rathjen	Tumour necrosis factor binding ligands
US6750325B1 (en)	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GR1001050B (el) *	1990-01-09	1993-04-28	Protein Design Labs Inc	Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
HUT60768A (en)	1990-03-16	1992-10-28	Sandoz Ag	Process for producing cd25 fixing molecules
GB9020282D0 (en)	1990-09-17	1990-10-31	Gorman Scott D	Altered antibodies and their preparation
US5858725A (en) *	1990-10-10	1999-01-12	Glaxo Wellcome Inc.	Preparation of chimaeric antibodies using the recombinant PCR strategy
US5994510A (en) *	1990-12-21	1999-11-30	Celltech Therapeutics Limited	Recombinant antibodies specific for TNFα
CZ333796A3 (cs) *	1991-03-06	1998-06-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
IL101147A (en) *	1991-03-07	2004-06-20	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
ES2118820T3 (es) *	1991-04-05	1998-10-01	Univ Washington	Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.
AU668349B2 (en) *	1991-04-25	1996-05-02	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human interleukin 6 receptor
EP0519596B1 (en) *	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
DE69233254T2 (de) *	1991-06-14	2004-09-16	Genentech, Inc., South San Francisco	Humanisierter Heregulin Antikörper
GB9115010D0 (en) *	1991-07-11	1991-08-28	Wellcome Found	Antibody
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
CA2113720A1 (en) *	1991-07-25	1993-02-04	Syamal Raychaudhuri	Induction of cytotoxic t-lymphocyte responses
US6136310A (en)	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
US5756096A (en) *	1991-07-25	1998-05-26	Idec Pharmaceuticals Corporation	Recombinant antibodies for human therapy
US5709860A (en) *	1991-07-25	1998-01-20	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
IE922437A1 (en) *	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US6329509B1 (en)	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
US6685939B2 (en)	1991-08-14	2004-02-03	Genentech, Inc.	Method of preventing the onset of allergic disorders
DE69230545T2 (de) *	1991-08-21	2000-07-06	Novartis Ag, Basel	Antikörperderivate
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
JP3024311B2 (ja) *	1991-10-03	2000-03-21	味の素株式会社	Ｉｌ−２受容体重鎖に結合するポリペプチド
US7070777B1 (en)	1991-11-15	2006-07-04	The Trustees Of Columbia University In The City Of New York	Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) *	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5817310A (en) *	1991-12-02	1998-10-06	Cor Therapeutics, Inc.	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
CA2103887C (en) *	1991-12-13	2005-08-30	Gary M. Studnicka	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) *	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
US5777085A (en) *	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
US5824307A (en)	1991-12-23	1998-10-20	Medimmune, Inc.	Human-murine chimeric antibodies against respiratory syncytial virus
DE69334351D1 (de) *	1992-02-06	2011-05-12	Novartis Vaccines & Diagnostic	Biosynthetisches Bindeprotein für Tumormarker
GB9203459D0 (en) *	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) *	1992-03-11	1995-02-07	Ciba Corning Diagnostics Corp.	MN gene and protein
US7381803B1 (en)	1992-03-27	2008-06-03	Pdl Biopharma, Inc.	Humanized antibodies against CD3
US6129914A (en) *	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
US6033667A (en) *	1992-05-05	2000-03-07	Cytel Corporation	Method for detecting the presence of P-selectin
US5874082A (en) *	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) *	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5639641A (en) *	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5958708A (en) *	1992-09-25	1999-09-28	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) *	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9223377D0 (en) *	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (de) *	1992-11-13	2003-04-15	Idec Pharma Corp	Konsensus-kozak-sequenzen zur säugetier- exprimierung
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5804187A (en) *	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
ATE182625T1 (de) *	1993-01-12	1999-08-15	Biogen Inc	Rekombinante anti-vla4 antikörpermoleküle
US5817311A (en) *	1993-03-05	1998-10-06	Universite Catholique De Louvain	Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) *	1993-03-05	1998-03-24	Universite Catholique Delouvain	LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) *	1993-03-05	1999-09-14	Universite Catholique De Louvain	Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
FI955261L (fi) *	1993-05-04	1996-01-03	Cytel Corp	P-selektiinin vasta-aineita ja niiden käyttö
WO1994028025A1 (en) *	1993-05-28	1994-12-08	The Scripps Research Institute	Methods and compositions for inhibiting cd14 mediated cell activation
TW458985B (en) *	1993-05-31	2001-10-11	Chugai Pharmaceutical Co Ltd	Reconstructed human antibody against human interleukin-6
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
SK285556B6 (sk) *	1993-09-07	2007-03-01	Smithkline Beecham Corporation	Fúzny proteín so špecifickou väzbou na ľudský IL-4, molekula nukleovej kyseliny, monoklonálne protilátky, farmaceutická kompozícia a použitie
ZA946875B (en) *	1993-09-07	1995-07-06	Smithkline Beecham Corp	Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5928904A (en) *	1993-09-07	1999-07-27	Smithkline Beecham Corporation	DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en)	1993-09-07	2002-12-19	Smithkline Beecham P.L.C.	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) *	1993-09-07	1999-06-22	Smithkline Beecham Corporation	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6214973B1 (en)	1993-11-19	2001-04-10	Chugai Seiyaku Kabushiki Kaisha	Reshaped human antibody to human medulloblastoma cells
WO1995015181A1 (en) *	1993-11-30	1995-06-08	Protein Design Labs, Inc.	Reperfusion therapy using antibodies to l-selectin
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en)	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
AU703152B2 (en) *	1994-01-25	1999-03-18	Biogen Ma Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1995026403A1 (en)	1994-03-29	1995-10-05	Celltech Therapeutics Limited	Antibodies against e-selectin
US5635597A (en) *	1994-05-27	1997-06-03	Affymax Technologies, N.V.	Peptides that bind IL-2 receptors
US5622701A (en) *	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
USRE39548E1 (en) *	1994-06-17	2007-04-03	Celltech R&D Limited	Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US6048972A (en) *	1994-07-13	2000-04-11	Chugai Pharmaceutical Co., Ltd.	Recombinant materials for producing humanized anti-IL-8 antibodies
DE4425115A1 (de) *	1994-07-15	1996-01-18	Boehringer Mannheim Gmbh	Verfahren zur Modifizierung der Stabilität von Antikörpern
EP0696455A1 (en) *	1994-08-11	1996-02-14	Cellena (Cell Engineering) A.G.	Transferrin compositions to alleviate the side effects of cytotoxic drugs
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5707621A (en) *	1994-08-31	1998-01-13	Chugai Pharmaceutical Co., Ltd.	Supression of nephritis-induced protein excretion by anti-IL-8
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5811524A (en) *	1995-06-07	1998-09-22	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7153508B2 (en)	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en)	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
AU6171196A (en) *	1995-06-07	1996-12-30	Sloan-Kettering Institute For Cancer Research	Therapeutic uses of ta99
US6001358A (en) *	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en)	1995-11-07	2002-08-27	Idec Pharmaceuticals Corporation	Methods of treating autoimmune diseases with gp39-specific antibodies
GB9600660D0 (en)	1996-01-12	1996-03-13	Ciba Geigy Ag	Protein
AU2527397A (en) *	1996-03-13	1997-10-01	Protein Design Labs, Inc.	Fas ligand fusion proteins and their uses
US5882644A (en) *	1996-03-22	1999-03-16	Protein Design Labs, Inc.	Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6713305B1 (en)	1996-04-29	2004-03-30	Novartis Ag	Metastasis-associated antigen and antibodies thereto
EP1378525A3 (en)	1996-06-07	2004-01-14	Neorx Corporation	Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
US6833255B1 (en)	1996-07-24	2004-12-21	Novartis, Ag	Drosophila melanogaster p70 S6 kinase
US6534311B2 (en)	1996-07-24	2003-03-18	Novartis Ag	Drosophila melanogaster p70S6 kinase
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
CA2264968A1 (en) *	1996-09-02	1998-03-12	Sumitomo Electric Industries, Ltd.	Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
US6013256A (en) *	1996-09-24	2000-01-11	Protein Design Labs, Inc.	Method of preventing acute rejection following solid organ transplantation
EP0962467A4 (en)	1996-09-26	2002-10-30	Chugai Pharmaceutical Co Ltd	Antibody against human parathormone related peptides
UA76934C2 (en)	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en)	1996-10-10	2011-02-08	Dyadic International (Usa), Inc.	Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US20020160005A1 (en)	1996-11-15	2002-10-31	Trustees Of Tufts College	Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en)	1996-11-15	2011-03-22	Trustees Of Tufts College	Human neutralizing antibodies against hemolytic uremic syndrome
ES2144386T5 (es)	1996-12-23	2012-12-07	Immunex Corporation	Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
US6262238B1 (en) *	1997-01-14	2001-07-17	Roche Diagnostic, Gmbh	Process for modifying the stability of antibodies
US6590079B2 (en)	1997-01-30	2003-07-08	Ixsys, Incorporated	Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en)	1998-01-30	2003-07-22	Ixsys, Incorporated	Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US7749498B2 (en)	1997-03-10	2010-07-06	Genentech, Inc.	Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en)	1997-03-10	2006-10-19	Jin-An Jiao	Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en)	1997-03-10	1999-11-16	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en)	2001-11-21	2003-06-12	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
ZA982371B (en) *	1997-03-21	1998-09-28	Sankyo Co	Humanized anti-human fas antibody
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
CN100480269C (zh)	1997-04-07	2009-04-22	基因技术股份有限公司	抗-血管内皮生长因子的抗体
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
AU750021C (en)	1997-05-15	2003-10-16	Chugai Seiyaku Kabushiki Kaisha	Cachexia remedy
JP2002512624A (ja) *	1997-05-21	2002-04-23	バイオベーションリミテッド	非免疫原性タンパク質の製造方法
JP4891477B2 (ja)	1997-10-02	2012-03-07	マックス−プランク−ゲゼルシャフトツールフォーデルングデルヴィッセンシャフテンエー．ヴェー．	血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
KR100473836B1 (ko) *	1997-10-03	2005-03-07	츄가이 세이야꾸 가부시키가이샤	천연 인간형화 항체
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1745799B1 (en)	1998-03-04	2015-09-02	The Trustees of The University of Pennsylvania	Compositions and methods of treating tumors
CA2325346A1 (en)	1998-04-03	1999-10-14	Chugai Seiyaku Kabushiki Kaisha	Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
CN1320044A (zh)	1998-08-11	2001-10-31	Idec药物公司	包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
JP4689781B2 (ja) *	1998-09-03	2011-05-25	独立行政法人科学技術振興機構	アミノ酸輸送蛋白及びその遺伝子
SK287601B6 (sk)	1998-09-14	2011-03-04	Board Of Regents, The University Of Texas System	Použitie protilátky alebo jej fragmentu viažuceho antigén na výrobu farmaceutickej kompozície na liečenie mnohonásobného myelómu a na inhibíciu resorpcie kostí
KR100618495B1 (ko)	1998-10-06	2006-08-31	마크 아론 에말파브	섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서
DE69839740D1 (de)	1998-10-22	2008-08-28	Univ Montana	Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
EP1131093A4 (en)	1998-11-09	2002-05-02	Idec Pharma Corp	TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
GB9825632D0 (en)	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
US20030035798A1 (en)	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
AU767066B2 (en)	1999-03-03	2003-10-30	Curis, Inc.	Methods of modulating lipid metabolism and storage
GB9906380D0 (en) *	1999-03-19	1999-05-12	Melvin William T	Monoclonal antibodies specific for cypibi
KR100746522B1 (ko)	1999-04-22	2007-08-07	바이오겐 아이덱 엠에이 인코포레이티드	인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
IT1306704B1 (it)	1999-05-26	2001-10-02	Sirs Societa Italiana Per La R	Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
CA2375827C (en)	1999-06-01	2017-01-10	Biogen, Inc.	A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US7144991B2 (en)	1999-06-07	2006-12-05	Aletheon Pharmaceuticals, Inc.	Streptavidin expressed gene fusions and methods of use thereof
US6531580B1 (en)	1999-06-24	2003-03-11	Ixsys, Inc.	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
TWI255718B (en)	1999-07-02	2006-06-01	Chugai Pharmaceutical Co Ltd	Ameliorative agent for low vasopressin concentration
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7253263B1 (en) *	1999-09-30	2007-08-07	Kyowa Hakko Kogyo Co., Ltd.	Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
PT1234031T (pt)	1999-11-30	2017-06-26	Mayo Foundation	B7-h1, uma nova molécula imunoregulatória
NZ519447A (en)	1999-12-16	2004-03-26	Biogen Inc	Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
ATE474854T1 (de)	2000-01-27	2010-08-15	Medimmune Llc	Rsv neutralisierende antikörper mit sehr hohen affinität
MXPA02007449A (es) *	2000-02-03	2003-04-14	Millennium Pharm Inc	Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos.
EP1259544B1 (en)	2000-02-11	2011-08-24	Biogen Idec MA Inc.	Heterologous polypeptide of the tnf family
DZ3295A1 (fr)	2000-02-24	2001-08-30		Anticorps humanises sequestrant un peptide amyloide .beta.
US7700735B2 (en)	2000-03-01	2010-04-20	Medimmune, Llc	High potency recombinant antibodies and method for producing them
AU4574501A (en)	2000-03-17	2001-10-03	Millennium Pharm Inc	Method of inhibiting stenosis and restenosis
US20010046496A1 (en)	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
ATE420661T1 (de)	2000-04-28	2009-01-15	Chugai Pharmaceutical Co Ltd	Zellproliferation-inhibitoren
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
AU2001261103B2 (en)	2000-04-29	2007-08-23	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
US7476383B2 (en)	2000-05-02	2009-01-13	The Uab Research Foundation	Antibody selective for DR4 and uses thereof
TWI318983B (en)	2000-05-02	2010-01-01	Uab Research Foundation	An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en)	2000-05-02	2007-10-09	The Uab Research Foundation	Combinations of DR5 antibodies and other therapeutic agents
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
EP1326896B1 (en)	2000-10-02	2010-11-24	Novartis Vaccines and Diagnostics, Inc.	Human anti-cd40 antibodies
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en)	2000-11-28	2006-01-24	Celltech R & D, Inc.	Compositions and methods for diagnosing or treating psoriasis
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
MXPA03009115A (es)	2001-04-06	2004-11-22	Univ Bristol	Uso de moleculas de enlace de cd25 en pacientes resistentes a esteroides.
HUP0402250A3 (en)	2001-04-13	2007-06-28	Biogen Idec Inc	Antibodies to vla-1
CN1541226A (zh) *	2001-05-18	2004-10-27	��ָ��Ӣ��ķ��Ϲ�˾	CD44v6特异性的抗体
US6972324B2 (en)	2001-05-18	2005-12-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Antibodies specific for CD44v6
US7541443B2 (en) *	2001-06-14	2009-06-02	Tolerrx, Inc.	Anti-CD4 antibodies
WO2002102973A2 (en)	2001-06-20	2002-12-27	Prochon Biotech Ltd.	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030013081A1 (en)	2001-06-26	2003-01-16	Olson William C.	Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4675512B2 (ja) *	2001-07-10	2011-04-27	三井化学株式会社	熱殺菌方法
AU2002365196C1 (en)	2001-07-19	2009-08-13	Perlan Therapeutics, Inc.	Multimeric proteins and methods of making and using same
DE60226036T9 (de) *	2001-08-03	2016-09-29	Medical & Biological Laboratories Co., Ltd.	ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
AU2002329775C1 (en)	2001-08-17	2011-04-07	Eli Lilly And Company	Assay method for alzheimer's disease
DK1434871T3 (en)	2001-09-20	2017-04-18	Immunex Corp	SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES
BR0213078A (pt)	2001-09-25	2004-11-23	Fujisawa Pharmaceutical Co	Anticorpo recombinante anti-osteopontina e uso do mesmo
GB0124317D0 (en)	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
US20030190705A1 (en) *	2001-10-29	2003-10-09	Sunol Molecular Corporation	Method of humanizing immune system molecules
ES2346517T3 (es) *	2001-11-12	2010-10-18	Merck Patent Gmbh	Anticuerpo modificado anti-tnf alfa.
EP1944043A1 (en)	2001-11-21	2008-07-16	The Trustees of the University of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2990322A1 (en)	2001-11-21	2003-06-05	The Trustees Of The University Of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP2298717B1 (en)	2001-11-30	2015-10-28	Biogen MA Inc.	Antibodies against monocyte chemotactic proteins
CA2468744C (en) *	2001-12-03	2013-05-14	Alexion Pharmaceuticals, Inc.	Hybrid antibodies
US7393648B2 (en)	2001-12-03	2008-07-01	Alexion Pharmaceuticals, Inc.	Hybrid antibodies
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
WO2003068821A2 (en) *	2002-02-14	2003-08-21	Immunomedics, Inc.	Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1478738B1 (en) *	2002-02-22	2008-11-12	Progenics Pharmaceuticals, Inc.	Anti-ccr5 antibody
EP2336184B1 (en)	2002-02-25	2014-12-03	Biogen Idec MA Inc.	Administration of agents for the treatment of inflammation
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CN102659946A (zh)	2002-03-13	2012-09-12	拜奥根Idec马萨诸塞公司	抗αvβ6抗体
AU2003225900A1 (en)	2002-03-20	2003-10-08	Pharmacia Corporation	Antibody disulfide isomers, use thereof, and methods of analyzing same
EP1576013A4 (en)	2002-03-22	2008-08-13	Amrad Operations Pty Ltd	MONOCLONAL ANTIBODY AGAINST THE INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RA1)
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
DE60333285D1 (de)	2002-05-14	2010-08-19	Martek Biosciences Corp	Carotinsynthase-gen und dessen verwendung
ES2370710T3 (es)	2002-05-28	2011-12-22	Ucb Pharma, S.A.	ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
AU2003232456B2 (en) *	2002-05-30	2009-06-04	Macrogenics, Inc.	CD16A binding proteins and use for the treatment of immune disorders
US7544483B2 (en)	2002-06-14	2009-06-09	Monier Tadros	Method for the production of protamine
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
GB0213745D0 (en)	2002-06-14	2002-07-24	Univ Edinburgh	Enzyme
JP2005535636A (ja)	2002-06-28	2005-11-24	アメリカ合衆国	インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
WO2010011999A2 (en)	2008-07-25	2010-01-28	The Regents Of The University Of California	Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
DK1578397T3 (da)	2002-11-15	2013-03-11	Genmab As	Humane monoklonale antistoffer mod CD25
CA2537263C (en)	2002-11-27	2017-05-30	Minerva Biotechnologies Corporation	Techniques and compositions for the diagnosis and treatment of cancer (muc1)
RS20100366A (sr)	2002-12-16	2011-04-30	Genentech, Inc.	Varijante imunoglobulina i njihova upotreba
CA2513113A1 (en)	2003-01-23	2004-08-05	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2004066931A2 (en)	2003-01-24	2004-08-12	Elan Pharmaceuticals Inc.	Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1460088A1 (en) *	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
US7321065B2 (en)	2003-04-18	2008-01-22	The Regents Of The University Of California	Thyronamine derivatives and analogs and methods of use thereof
PL1631312T3 (pl)	2003-04-23	2009-02-27	Squibb & Sons Llc	Kompozycje i sposoby terapii choroby zapalenia jelit
EP1631590B1 (en) *	2003-04-23	2011-07-27	Medarex, Inc.	Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
WO2005013889A2 (en)	2003-05-19	2005-02-17	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in lewy body disease
CA2528551A1 (en)	2003-06-13	2005-01-13	Biogen Idec Ma Inc.	Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US20060162014A1 (en)	2003-07-07	2006-07-20	Jaffe Eileen K	Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
US8153410B2 (en)	2003-07-07	2012-04-10	Fox Chase Cancer Center	Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
PL2784084T5 (pl)	2003-07-08	2024-12-02	Novartis Pharma Ag	Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
BRPI0412885A (pt)	2003-07-18	2006-10-03	Amgen Inc	polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
US7834155B2 (en)	2003-07-21	2010-11-16	Immunogen Inc.	CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
GB0321997D0 (en)	2003-09-19	2003-10-22	Novartis Ag	Organic compound
WO2005044857A1 (ja) *	2003-11-11	2005-05-19	Chugai Seiyaku Kabushiki Kaisha	ヒト化抗cd47抗体
JP2007514413A (ja)	2003-11-12	2007-06-07	プロジェニクス・ファーマスーティカルズ・インコーポレイテッド	Ｃ型肝炎ウイルス糖タンパク質をコードする新規配列
EP2070947B1 (en)	2003-12-05	2014-06-11	multimmune GmbH	Therapeutic and diagnostic anti-Hsp70 antibodies
AU2004297265A1 (en)	2003-12-08	2005-06-23	Eisai, Inc.	Antibodies that specifically bind PMS2
JP2008504222A (ja)	2003-12-15	2008-02-14	アレクシオンファーマシューティカルズ，インコーポレイテッド	新規の抗ｄｃ−ｓｉｇｎ抗体
ITRM20030601A1 (it) *	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
SI2311873T1 (sl)	2004-01-07	2018-12-31	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specifična monoklonska protitelesa in njihova uporaba
US20070280950A1 (en)	2004-01-19	2007-12-06	Medical And Biological Laboratories Co., Ltd.	Inflammatory Cytokine Inhibitors
EP1728077A4 (en)	2004-01-30	2008-11-05	Dana Farber Cancer Inst Inc	METHOD FOR DETERMINING AND QUANTIFYING A RADIATION OR GENOTOXIN EXPOSURE
EP1713503B1 (en)	2004-02-10	2013-07-31	The Regents of the University of Colorado, a Body Corporate	Inhibition of factor b, the alternative complement pathway and methods related thereto
TWI359026B (en)	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
CA2556027C (en)	2004-02-12	2015-11-24	Morphotek, Inc.	Monoclonal antibodies that specifically block biological activity of a tumor antigen
JP4824547B2 (ja)	2004-02-20	2011-11-30	インテレクトニュウロサイエンシス，インク．	モノクローナル抗体およびその利用
WO2005090406A2 (en)	2004-03-12	2005-09-29	Vasgene Therapeutics, Inc.	Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US7625549B2 (en)	2004-03-19	2009-12-01	Amgen Fremont Inc.	Determining the risk of human anti-human antibodies in transgenic mice
AU2005227313A1 (en)	2004-03-19	2005-10-06	Amgen Inc.	Reducing the risk of human and anti-human antibodies through V gene manipulation
MXPA06011199A (es)	2004-03-31	2007-04-16	Genentech Inc	Anticuerpos anti-tgf-beta humanizados.
MY162179A (en)	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
EP2394662B1 (en)	2004-04-02	2018-03-21	The Regents of The University of California	Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CA2568201C (en)	2004-05-24	2013-07-30	Universitat Zu Koln	Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (en)	2004-06-04	2005-12-07	University of Geneva	Novel means and methods for the treatment of hearing loss and phantom hearing
RU2412202C2 (ru)	2004-06-21	2011-02-20	Медарекс, Инк.	Антитела рецептора 1 интерферона альфа и их применение
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
JP5102028B2 (ja)	2004-07-26	2012-12-19	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗ｃｄ１５４抗体
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
EA013752B1 (ru)	2004-08-09	2010-06-30	Элан Фармасьютикалз, Инк.	Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CA2478458A1 (en)	2004-08-20	2006-02-20	Michael Panzara	Treatment of pediatric multiple sclerosis
FI20041204A0 (fi)	2004-09-16	2004-09-16	Riikka Lund	Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
AU2005291486A1 (en)	2004-10-01	2006-04-13	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Novel antibodies directed to the mammalian EAG1 ion channel protein
SI1810026T1 (en)	2004-10-06	2018-08-31	Mayo Foundation For Medical Education And Research	B7-h1 and pd-1 in treatment of renal cell carcinoma
WO2006047340A2 (en)	2004-10-22	2006-05-04	Amgen Inc.	Methods for refolding of recombinant antibodies
KR20070094890A (ko)	2004-10-25	2007-09-27	머크 앤드 캄파니 인코포레이티드	안티 ａｄｄｌ 항체 및 그 용도
US20090202527A1 (en)	2004-11-19	2009-08-13	Biogen Idec Ma Inc.	Treatment for multiple sclerosis
US8916165B2 (en)	2004-12-15	2014-12-23	Janssen Alzheimer Immunotherapy	Humanized Aβ antibodies for use in improving cognition
ES2320374T3 (es)	2005-01-05	2009-05-21	F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H.	Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
CN101107007B (zh)	2005-01-27	2011-08-17	奥克兰儿童医院及研究中心	对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
EP2357254A1 (en)	2005-02-14	2011-08-17	University of Iowa Research Foundation	Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP2529619B1 (en)	2005-02-17	2015-09-23	Biogen MA Inc.	Treating neurological disorders
WO2006090750A1 (ja)	2005-02-28	2006-08-31	Institute For Antibodies Co., Ltd.	抗IgSF4抗体及びその利用
DE602006016413D1 (de)	2005-03-02	2010-10-07	Biogen Idec Inc	Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
CA2600505C (en)	2005-03-10	2016-05-03	Morphotek, Inc.	Anti-mesothelin antibodies
EP1863531A1 (en)	2005-03-19	2007-12-12	Medical Research Council	Improvements in or relating to treatment and prevention of viral infections
PT2343320T (pt)	2005-03-25	2018-01-23	Gitr Inc	Anticorpos anti-gitr e as suas utilizações
ES2720288T3 (es)	2005-03-30	2019-07-19	Minerva Biotechnologies Corp	Proliferación de células que expresan MUC1
US8859495B2 (en)	2005-03-30	2014-10-14	Minerva Biotechnologies Corporation	Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
EP2674165B1 (en)	2005-03-31	2016-10-12	The General Hospital Corporation	Hepatocyte growth factor receptor agonist for increasing lymphangiogenesis
HUE052412T2 (hu)	2005-04-04	2021-04-28	Biogen Ma Inc	Módszerek egy gyógyászati hatóanyagra adott immunválasz kiértékelésére
WO2006116592A2 (en)	2005-04-22	2006-11-02	Morphotek, Inc.	Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1871809A2 (en)	2005-04-22	2008-01-02	Morphotek, Inc.	Antibodies with immune effector activity and that internalize in endosialin-positive cells
US20090041783A1 (en)	2005-04-28	2009-02-12	Mochida Pharmaceutical Co., Ltd.	Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006117782A2 (en)	2005-05-04	2006-11-09	Quark Pharmaceuticals, Inc.	Recombinant antibodies against cd55 and cd59 and uses thereof
RS54876B1 (sr)	2005-05-10	2016-10-31	Incyte Holdings Corp	Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
CA2609038A1 (en)	2005-05-18	2006-11-23	Trinity Biosystems, Inc.	Methods and compositions for immunizing against chlamydia infection
WO2006125207A2 (en)	2005-05-19	2006-11-23	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
ES2548700T3 (es)	2005-05-26	2015-10-20	The Regents Of The University Of Colorado, A Body Corporate	Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
EP2460832A3 (en)	2005-05-27	2012-10-31	Biogen Idec MA Inc.	TWEAK binding antibodies
EP1899376A2 (en)	2005-06-16	2008-03-19	The Feinstein Institute for Medical Research	Antibodies against hmgb1 and fragments thereof
US8901281B2 (en)	2005-06-17	2014-12-02	Merck Sharp & Dohme Corp.	ILT3 binding molecules and uses therefor
ES2439709T3 (es) *	2005-06-21	2014-01-24	Xoma (Us) Llc	Anticuerpos y fragmentos de los mismos que se unen a la IL-1beta
CN102875681A (zh)	2005-07-08	2013-01-16	拜奥根Idec马萨诸塞公司	抗-αvβ6抗体及其用途
FR2888850B1 (fr)	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
EP1910573B1 (en)	2005-07-22	2013-09-04	CytoDyn, Inc.	Methods for reducing viral load in hiv-1-infected patients
EP2311876A3 (en)	2005-07-28	2011-04-27	Novartis AG	M-CSF-specific monoclonal antibody and uses thereof
WO2007030560A2 (en)	2005-09-08	2007-03-15	Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine	Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
CN101313216A (zh)	2005-09-22	2008-11-26	普洛茨股份有限公司	酵母突变体中产生的糖基化多肽及其使用方法
EP1948680A4 (en)	2005-10-28	2010-01-13	Univ California	METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
CN101351221A (zh)	2005-10-28	2009-01-21	明治制果株式会社	绿脓杆菌的外膜蛋白pa5158
TWI424161B (zh)	2005-11-01	2014-01-21	Abbvie Biotechnology Ltd	利用生物標記診斷關節黏連脊椎炎之方法及組合物
JP2009516513A (ja)	2005-11-21	2009-04-23	ラボラトワールセローノソシエテアノニム	ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
KR20140087058A (ko)	2005-11-30	2014-07-08	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
JP2009523807A (ja)	2006-01-18	2009-06-25	ザジェネラルホスピタルコーポレイション	リンパ機能を高める方法
CA2635445A1 (en)	2006-02-22	2007-08-30	University Of Zurich	Methods for treating autoimmune or demyelinating diseases
WO2007106769A2 (en)	2006-03-10	2007-09-20	Zymogenetics, Inc.	Antibodies that bind both il-17a and il-17f and methods of using the same
EP2522727A1 (en)	2006-03-23	2012-11-14	Tohoku University	Highly functional bispecific antibody
CN101454446A (zh)	2006-03-30	2009-06-10	明治制果株式会社	绿脓杆菌的外膜蛋白pa0427
TWI392684B (zh)	2006-04-05	2013-04-11	亞培生物科技公司	抗體之純化
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
EP2703010A3 (en)	2006-04-10	2014-08-06	AbbVie Biotechnology Ltd	Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (en)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Uses and compositions for treatment of psoriatic arthritis
JP5496658B2 (ja)	2006-05-25	2014-05-21	バイオジェン・アイデック・エムエイ・インコーポレイテッド	脳卒中を処置する方法
BRPI0711229A2 (pt)	2006-05-31	2013-01-08	Astellas Pharma Inc	anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana
CA2653628C (en)	2006-06-01	2015-07-14	Elan Pharmaceuticals, Inc.	Neuroactive fragments of app
WO2007144893A2 (en)	2006-06-15	2007-12-21	Fibron Ltd.	Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
JP5597793B2 (ja)	2006-06-19	2014-10-01	メルク・シャープ・アンド・ドーム・コーポレーション	Ｉｌｔ３結合分子およびその使用
KR101396797B1 (ko)	2006-06-30	2014-05-26	애브비 바이오테크놀로지 리미티드	자동 주사 장치
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
EP2292648A3 (en)	2006-07-07	2011-06-08	Intercell AG	Small Streptococcus pyogenes antigens and their use
EP2078732B1 (en)	2006-07-10	2015-09-16	Fujita Health University	Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
JP2009542810A (ja)	2006-07-10	2009-12-03	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
EP2057193B1 (en)	2006-08-04	2013-12-18	Novartis AG	Ephb3-specific antibody and uses thereof
JP2010502573A (ja)	2006-08-11	2010-01-28	ユニヴァーシティオブメディスンアンドデンティストリーオブニュージャージー	二重増感剤含有ルミネッセンス化合物および結合体、ならびにその使用
PL2059535T3 (pl)	2006-08-18	2014-04-30	Novartis Ag	Przeciwciało specyficzne względem PRLR i jego zastosowanie
EP2500415A1 (en)	2006-09-13	2012-09-19	Abbott Laboratories	Cell culture improvements
CA2842964A1 (en)	2006-09-13	2008-03-20	Abbvie Inc.	Cell culture improvements
US20100297103A1 (en)	2006-09-14	2010-11-25	Medical & Biological Laboratories Co., Ltd.	Antibody having enhanced adcc activity and method for production thereof
FR2906533B1 (fr)	2006-09-28	2013-02-22	Pf Medicament	Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
EP2433966A1 (en)	2006-11-03	2012-03-28	U3 Pharma GmbH	FGFR4 antibodies
CN101631802B (zh)	2006-11-10	2014-03-05	株式会社立富泰克	在体内具有抗肿瘤活性的抗人Dlk-1抗体
KR20090078353A (ko)	2006-11-17	2009-07-17	노파르티스 아게	Ｌｉｎｇｏ 결합 분자 및 그의 제약학적 용도
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US8288110B2 (en)	2006-12-04	2012-10-16	Perkinelmer Health Sciences, Inc.	Biomarkers for detecting cancer
KR20140119831A (ko)	2006-12-07	2014-10-10	노파르티스 아게	Ｅｐｈｂ３에 대한 길항제 항체
US8680252B2 (en)	2006-12-10	2014-03-25	Dyadic International (Usa), Inc.	Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US8440185B2 (en)	2006-12-26	2013-05-14	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
EP2124998B8 (en)	2006-12-27	2015-05-06	The Johns Hopkins University	Methods for detecting inflammation and auto-immune diseases
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
PL2118309T3 (pl)	2006-12-29	2015-07-31	Univ Colorado Regents	Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania
DK2099826T3 (da)	2007-01-05	2014-01-20	Univ Zuerich	Anti-beta-amyloid-antistof og anvendelser deraf
JP5437813B2 (ja)	2007-01-12	2014-03-12	インターセルアーゲー	Ｓ．アガラクティエの防御タンパク質、その組み合わせ、およびそれを使用する方法
US8168415B2 (en)	2007-02-07	2012-05-01	The Regents Of The University Of Colorado	Axl fusion proteins as Axl tyrosine kinase inhibitors
PT2130044T (pt)	2007-02-16	2017-02-03	Genzyme Corp	Método para a identificação de risco de distúrbio da tiróide
ES2546863T3 (es)	2007-02-23	2015-09-29	Prothena Biosciences Limited	Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
EP2124988B1 (en)	2007-02-23	2014-11-12	The Trustees of Columbia University in the City of New York	Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
PL2583978T3 (pl)	2007-02-23	2016-07-29	Prothena Biosciences Ltd Co	Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
PT2457928T (pt)	2007-03-13	2017-08-17	Univ Zuerich	Anticorpo monoclonal humano específico de tumores
BRPI0809042B1 (pt)	2007-03-22	2021-08-31	Biogen Ma Inc.	Proteína de ligação a cd154 isolada, seu uso, e composição
SI2137217T1 (sl)	2007-04-05	2014-07-31	Morphotek, Inc.	Postopki za inhibiranje vezave endosialina na ligande
EP2150564A2 (en)	2007-04-27	2010-02-10	ZymoGenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
AU2008248755A1 (en)	2007-05-02	2008-11-13	Intercell Ag	Klebsiella antigens
EP3456733A1 (en)	2007-05-11	2019-03-20	Genzyme Corporation	Methods of producing a secreted protein
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
US7709215B2 (en)	2007-06-01	2010-05-04	Cytonics Corporation	Method for diagnosing and treating acute joint injury
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
ES2707815T3 (es)	2007-06-14	2019-04-05	Biogen Ma Inc	Formulaciones de anticuerpo natalizumab
CN101883782A (zh)	2007-06-18	2010-11-10	英特塞尔股份公司	衣原体抗原
JP5602625B2 (ja)	2007-06-26	2014-10-08	エフ−スタービオテヒノロギッシェフォルシュングス− ウントエントヴィッケルングスゲゼルシャフトミットベシュレンクテルハフツング	結合物質のディスプレイ
EP2168599B1 (en)	2007-06-27	2016-08-10	Osaka University	Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
DK2175884T3 (en)	2007-07-12	2016-09-26	Gitr Inc	Combination USING GITR BINDING MOLECULES
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2514762B1 (en)	2007-07-13	2015-04-08	The Johns Hopkins University	B7-DC variants
US8551751B2 (en)	2007-09-07	2013-10-08	Dyadic International, Inc.	BX11 enzymes having xylosidase activity
EP2543389A3 (en)	2007-08-02	2013-04-24	Gilead Biologics, Inc.	Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
AU2008292352B2 (en)	2007-08-30	2012-03-08	Daiichi Sankyo Company, Limited	Anti-EPHA2 antibody
WO2009031230A1 (ja) *	2007-09-06	2009-03-12	Osaka University	抗ｃｄ２０モノクローナル抗体
US20100239570A1 (en)	2007-09-13	2010-09-23	Roger Nitsch	Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
US20100226925A1 (en)	2007-09-14	2010-09-09	Amgen Inc.	Homogeneous Antibody Populations
ES2677246T3 (es)	2007-10-11	2018-07-31	Daiichi Sankyo Company, Limited	Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2210901A4 (en)	2007-10-19	2012-04-25	Immunas Pharma Inc	FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
US20100324154A1 (en)	2007-11-01	2010-12-23	Hageman Gregory S	Assessing susceptibility to vascular disorders
PL2207808T3 (pl)	2007-11-02	2013-11-29	Novartis Ag	Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne
CA2703621C (en)	2007-11-09	2022-03-22	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as antimicrobials
MY155621A (en)	2007-11-12	2015-11-13	U3 Pharma Gmbh	Axl antibodies
PT2220241T (pt)	2007-11-28	2016-12-26	Univ Pennsylvania	Adenovírus compreendendo uma proteína hexão da cápside do adenovírus e símio sadv-39 e suas utilizações
JP5758124B2 (ja)	2007-11-28	2015-08-05	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	サルサブファミリーＣアデノウイルスＳＡｄＶ−４０、−３１および−３４ならびにそれらの用途
US8815237B2 (en)	2007-12-05	2014-08-26	Massachusetts Institute Of Technology	Aglycosylated immunoglobulin mutants
EP2231181B1 (en)	2007-12-17	2016-02-17	Marfl AB	New vaccine for the treatment of mycobacterium related disorders
KR20100100941A (ko)	2007-12-25	2010-09-15	메이지 세이카 가부시키가이샤	녹농균의 ⅲ형 분비 장치 구성 단백질 ｐａ1698
EA028356B1 (ru)	2007-12-28	2017-11-30	Протена Байосайенсиз Лимитед	Лечение и профилактика амилоидоза
DK2242769T3 (en)	2008-01-11	2017-02-06	Adheron Therapeutics Inc	ANTI-CADHERIN-11 EC1 DOMAIN ANTIBODIES FOR TREATMENT OF INFLAMMATORY LED DISEASES
KR101597842B1 (ko)	2008-01-11	2016-02-25	가부시키가이샤 진 테크노 사이언스	인간화된 항-알파9 인테그린 항체 및 그의 용도
CN101918549B (zh)	2008-01-11	2012-11-28	财团法人化学及血清疗法研究所	改良的人源化的抗-人α9-整联蛋白抗体
EP3121277B1 (en)	2008-02-08	2018-04-11	Immunas Pharma, Inc.	Antibody capable of binding specifically to ab-oligomer, and use thereof
WO2009136977A2 (en)	2008-03-04	2009-11-12	The Trustees Of The University Of Pennsylvania	Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
KR20100135807A (ko)	2008-03-13	2010-12-27	바이오테스트 아게	질병 치료제
CN102027018A (zh)	2008-03-13	2011-04-20	生物测试股份公司	一种治疗疾病的试剂
EP2265643B1 (en)	2008-03-13	2016-10-19	Biotest AG	Dosing regimen for treating psoriasis and rheumatoid arthritis
EP2664339A3 (en)	2008-03-17	2013-12-11	Universitätsklinikum Münster	YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
JP2011514167A (ja)	2008-03-17	2011-05-06	インターセルアーゲー	肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
EP2275537B1 (en)	2008-03-17	2014-12-24	Livtech Inc.	Anti-human dlk-1 antibody having anti-tumor activity in vivo
EP2260863A1 (en)	2008-03-27	2010-12-15	Takara Bio, Inc.	Prophylactic/therapeutic agent for infectious disease
KR101674097B1 (ko)	2008-04-11	2016-11-08	시애틀 지네틱스, 인크.	췌장, 난소 및 다른 암의 검출 및 치료
EP2113255A1 (en)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Cytotoxic immunoglobulin
PL2282773T3 (pl)	2008-05-02	2014-08-29	Seattle Genetics Inc	Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
WO2009149021A2 (en)	2008-06-02	2009-12-10	Dana-Farber Cancer Institute, Inc.	Xbp1, cd138, and cs1 peptides
US8575314B2 (en)	2008-06-20	2013-11-05	National University Corporation Okayama University	Antibody against oxidized LDL/β2GPI complex and use of the same
TR201808591T4 (tr)	2008-06-25	2018-07-23	Esbatech Alcon Biomed Res Unit	Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
PL3628686T3 (pl)	2008-06-25	2022-02-28	Novartis Ag	Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
EP2307457B2 (en)	2008-06-25	2022-06-22	Novartis AG	Stable and soluble antibodies inhibiting tnf
SMT201800206T1 (it)	2008-07-08	2018-05-02	Incyte Holdings Corp	1,2,5-ossadiazoli come inibitori di indoleamina 2,3-diossigenasi
EP2322610B1 (en)	2008-07-16	2016-12-14	Medical and Biological Laboratories Co., Ltd.	Anti-human clcp1 antibody and use thereof
CA2732715C (en)	2008-08-01	2015-04-07	Kusuki Nishioka	Treatment agent or preventative agent for osteoarthritis
US8795981B2 (en)	2008-08-08	2014-08-05	Molecular Devices, Llc	Cell detection
US8417011B2 (en)	2008-09-18	2013-04-09	Molecular Devices (New Milton) Ltd.	Colony detection
EP2172485A1 (en)	2008-10-01	2010-04-07	Pierre Fabre Medicament	Novel anti CXCR4 antibodies and their use for the treatment of cancer
US8715654B2 (en)	2008-10-02	2014-05-06	Celtaxsys, Inc.	Methods of modulating the negative chemotaxis of immune cells
US11898160B2 (en)	2008-10-09	2024-02-13	Minerva Biotechnologies Corporation	Method for maintaining pluripotency in cells
ES2732504T3 (es)	2008-10-29	2019-11-22	Circular Commitment Company	Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US8940290B2 (en)	2008-10-31	2015-01-27	The Trustees Of The University Of Pennsylvania	Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
AR074439A1 (es)	2008-12-02	2011-01-19	Pf Medicament	Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
US9469691B2 (en)	2008-12-02	2016-10-18	Pierre Fabre Medicament	Anti-cMET antibody
AU2009328505B2 (en)	2008-12-19	2014-11-27	Panima Pharmaceuticals Ag	Human anti-alpha-synuclein autoantibodies
US8313915B2 (en)	2009-01-21	2012-11-20	Gundersen Lutheran Medical Foundation, Inc.	Early detection of canine lyme disease by specific peptides and antibodies
US20100260752A1 (en)	2009-01-23	2010-10-14	Biosynexus Incorporated	Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
EP2424882A2 (en)	2009-02-05	2012-03-07	Intercell AG	Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en)	2009-02-13	2010-08-19	Intercell Ag	Nontypable haemophilus influenzae antigens
US20110306069A1 (en)	2009-02-19	2011-12-15	Qingyu Wu	Corin As A Marker For Heart Failure
CA2754764A1 (en)	2009-03-10	2010-09-16	Baylor Research Institute	Antigen presenting cell targeted cancer vaccines
CN106432493B (zh)	2009-03-10	2020-01-31	贝勒研究院	抗-cd40抗体及其用途
CN105884903B (zh)	2009-03-10	2019-12-06	贝勒研究院	靶向抗原呈递细胞的疫苗
US9315584B2 (en)	2009-03-25	2016-04-19	Tohoku University	LH-type bispecific antibody
SG10201401331TA (en)	2009-04-09	2014-10-30	Daiichi Sankyo Co Ltd	Anti-siglec-15 antibody
JP2012523438A (ja)	2009-04-10	2012-10-04	タフツメディカルセンターインコーポレイテッド	メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
WO2010119704A1 (en)	2009-04-17	2010-10-21	Immunas Pharma, Inc.	Antibodies that specifically bind to a beta oligomers and use thereof
EP2246364A1 (en)	2009-04-29	2010-11-03	Pierre Fabre Médicament	Anti CXCR4 antibodies for the treatment of HIV
CA2760237C (en)	2009-04-29	2017-11-14	Abbott Biotechnology Ltd.	Automatic injection device and plunger for same
WO2012055980A1 (en)	2010-10-27	2012-05-03	Pierre Fabre Medicament	Antibodies for the treatment of hiv
EP2270053A1 (en)	2009-05-11	2011-01-05	U3 Pharma GmbH	Humanized AXL antibodies
EP2435559A1 (en)	2009-05-29	2012-04-04	The Trustees Of The University Of Pennsylvania	Simian adenovirus 41 and uses thereof
EP2260864A1 (en)	2009-06-10	2010-12-15	University of Melbourne	Therapeutic applications
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CA2767409C (en)	2009-07-24	2018-10-30	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
CN102548466A (zh)	2009-07-28	2012-07-04	霍夫曼-拉罗奇有限公司	非侵入性体内光学成像方法
US20120164659A1 (en)	2009-08-05	2012-06-28	Nexigen Gmbh	Human hcv-interacting proteins and methods of use
WO2011024114A1 (en)	2009-08-25	2011-03-03	Ecole Polytechnique Federale De Lausanne (Epfl)	Targeting extracellular matrix molecules for the treatment of cancer
TWI412375B (zh)	2009-08-28	2013-10-21	Roche Glycart Ag	人類化抗ｃｄｃｐ１抗體
EP2473523A2 (en)	2009-08-31	2012-07-11	Amplimmune, Inc.	Methods and compositions for the inhibition of transplant rejection
EP2477647B1 (en)	2009-09-14	2016-01-13	The Regents of the University of Colorado	Modulation of yeast-based immunotherapy products and responses
EP2305285A1 (en)	2009-09-29	2011-04-06	Julius-Maximilians-Universität Würzburg	Means and methods for treating ischemic conditions
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
EP2308897A1 (en)	2009-10-09	2011-04-13	Pierre Fabre Medicament	Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2485762B1 (en)	2009-10-11	2017-12-13	Biogen MA Inc.	Anti-vla-4 related assays
EP2502936B1 (en)	2009-11-18	2016-01-06	Tohoku University	Highly-functional mutant of humanized anti-egfr antibody variable region
EP2332929A1 (en)	2009-11-25	2011-06-15	ArisGen SA	Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
WO2011068870A2 (en)	2009-12-01	2011-06-09	President And Fellows Of Harvard College	Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
EP2513144A1 (en)	2009-12-16	2012-10-24	Philip Bosch	Methods of treating interstitial cystitis
US9221759B2 (en)	2010-01-13	2015-12-29	Rutgers, The State University Of New Jersey	Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
WO2011091177A1 (en)	2010-01-20	2011-07-28	Tolerx, Inc.	Anti-ilt5 antibodies and ilt5-binding antibody fragments
JP5947727B2 (ja)	2010-01-20	2016-07-06	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
JP2012246222A (ja)	2010-01-29	2012-12-13	Axis Inc	変形性関節症治療剤または予防剤を製造するための使用
WO2011093081A1 (ja)	2010-01-29	2011-08-04	Ａｘｉｓ株式会社	変形性関節症治療剤を含有する注射剤
KR20120115383A (ko)	2010-01-29	2012-10-17	가부시키가이샤 아크시스	변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법
WO2011097301A2 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
CN102844045A (zh)	2010-02-08	2012-12-26	艾更斯司股份有限公司	结合于161p2f10b蛋白的抗体药物偶联物(adc)
MX342270B (es)	2010-02-18	2016-09-21	The Regents Of The Univ Of California *	ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
EP2544688B1 (en)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Methods and compositions for treatment of angelman syndrome
US9216217B2 (en)	2010-03-03	2015-12-22	The University Of British Columbia	Oligomer-specific amyloid beta epitope and antibodies
US20130041349A1 (en)	2010-03-26	2013-02-14	Westfaelische Wilhelms-Universitaet Muenster	Substitute therapy for glucocorticoids
EP2371863A1 (en)	2010-03-30	2011-10-05	Pierre Fabre Médicament	Humanized anti CXCR4 antibodies for the treatment of cancer
ES2571994T3 (es)	2010-04-09	2016-05-27	Critical Care Diagnostics Inc	Anticuerpos contra ST-2 humana soluble y ensayos
LT2558499T (lt)	2010-04-16	2017-07-25	Biogen Ma Inc.	Antikūnai prieš vla-4
ES2727275T3 (es)	2010-04-21	2019-10-15	Abbvie Biotechnology Ltd	Dispositivo automático de inyección portátil para la liberación controlada de agentes terapéuticos
MX2012012736A (es)	2010-05-07	2013-02-26	Hoffmann La Roche	Metodo de diagnostico para la deteccion de celulas ex vivo.
BR112012029281B1 (pt)	2010-05-17	2020-12-08	Livtech, Inc	anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
WO2011146727A1 (en)	2010-05-19	2011-11-24	Philip Bosch	Methods of treating interstitial cystitis
CN102959097B (zh)	2010-07-08	2014-07-16	本田技研工业株式会社	高频加热用线圈
JP5934203B2 (ja)	2010-07-14	2016-06-15	メルク・シャープ・エンド・ドーム・コーポレイション	抗ａｄｄｌモノクローナル抗体およびこの使用
PT2593128T (pt)	2010-07-15	2018-04-17	Adheron Therapeutics Inc	Anticorpos humanizados visando o domínio ec1 de caderina-11 e composições e métodos relacionados
KR102080704B1 (ko)	2010-07-29	2020-02-24	세센 바이오, 아이엔씨.	키메라 il-1 수용체 유형 i 항진제 및 길항제들
JP2012034668A (ja)	2010-08-12	2012-02-23	Tohoku Univ	ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
WO2012027494A1 (en)	2010-08-24	2012-03-01	Regents Of The University Of Minnesota	Bispecific targeting reagents
US9034333B2 (en)	2010-08-27	2015-05-19	University Of Zurich	Method for target and drug validation in inflammatory and/or cardiovascular diseases
EP2609211A1 (en)	2010-08-27	2013-07-03	University of Zurich	A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en)	2010-09-01	2012-03-08	Eth Zürich, Institute Of Molecular Biology And Biophysics	Affinity purification system based on donor strand complementation
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US8497138B2 (en)	2010-09-30	2013-07-30	Genetix Limited	Method for cell selection
WO2012043747A1 (ja)	2010-09-30	2012-04-05	独立行政法人理化学研究所	グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
LT2627672T (lt)	2010-10-11	2018-12-10	Biogen International Neuroscience Gmbh	Žmogaus antikūnai prieš tau baltymą
BR112013009083B1 (pt)	2010-10-13	2021-08-10	Janssen Biotech, Inc.	Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada
ES2632486T3 (es)	2010-10-18	2017-09-13	Mediapharma S.R.L.	Anticuerpo de unión a ErbB3
ES2730941T7 (es)	2010-10-22	2020-05-27	Seattle Genetics Inc	Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
EP2632492B1 (en)	2010-10-25	2017-10-04	Biogen MA Inc.	METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
JP5918143B2 (ja)	2010-10-29	2016-05-18	第一三共株式会社	新規抗ｄｒ５抗体
WO2012068463A2 (en)	2010-11-18	2012-05-24	Beth Israel Deaconess Medicall Center, Inc.	Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
BR112013012396A2 (pt)	2010-11-19	2020-11-10	Toshio Imai	anticorpos anti-ccl20 de neutralização
AU2011332025B2 (en)	2010-11-23	2015-06-25	The Trustees Of The University Of Pennsylvania	Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
CA2818781C (en)	2010-12-17	2019-10-08	Neurimmune Holding Ag	Human anti-sod1 antibodies
EP2659910B1 (en)	2010-12-27	2016-11-09	National University Corporation Nagoya University	Screening method for a compound capable of suppressing receptor tyrosine kinase-mediated pro-survival signaling in a cancer cell
DK2663580T3 (en)	2011-01-10	2017-03-13	Ct Atlantic Ltd	COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
DK3604339T3 (da)	2011-01-14	2021-04-12	Univ California	Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
BR112013018905B1 (pt)	2011-01-24	2021-07-13	Abbvie Biotechnology Ltd	Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
WO2012104824A1 (en)	2011-02-04	2012-08-09	Ecole polytechnique fédérale de Lausanne (EPFL)	Therapeutic antibodies targeting app-c99
WO2012107589A1 (en)	2011-02-11	2012-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012110843A1 (en)	2011-02-18	2012-08-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
US20140044644A1 (en)	2011-02-21	2014-02-13	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
JP6385060B2 (ja)	2011-03-07	2018-09-05	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	治療的に活性な抗体のインビボにおける選択
WO2012119999A1 (en)	2011-03-07	2012-09-13	F. Hoffmann-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
EP2684045B2 (en)	2011-03-09	2023-03-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods to characterize patients suffering from hemolysis
WO2012125680A1 (en)	2011-03-16	2012-09-20	Novartis Ag	Methods of treating vasculitis using an il-17 binding molecule
CA2830503A1 (en)	2011-03-17	2012-09-20	Minerva Biotechnologies Corporation	Method for making pluripotent stem cells
JP5955871B2 (ja)	2011-03-17	2016-07-20	ミルテニイバイオテックゲゼルシャフトミットベシュレンクテルハフツング	Ｔｃｒアルファ／ベータを枯渇させた細胞調製物
AR085573A1 (es)	2011-03-25	2013-10-09	Baylor Res Inst	Composiciones y metodos de inmunizacion contra el virus de la hepatitis c
TW201249867A (en)	2011-04-01	2012-12-16	Astellas Pharma Inc	Novel anti-human il-23 receptor antibody
JP6066995B2 (ja)	2011-04-21	2017-01-25	アッヴィ・インコーポレイテッド	装着型自動注射装置
SG194620A1 (en)	2011-04-25	2013-12-30	Daiichi Sankyo Co Ltd	Anti-b7-h3 antibody
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR102014512B1 (ko)	2011-05-02	2019-08-26	밀레니엄 파머슈티컬스 인코퍼레이티드	항-α4β7 항체에 대한 제형
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012154889A1 (en)	2011-05-09	2012-11-15	The Cleveland Clinic Foundation	Serum s100b and uses thereof
WO2012163848A1 (en)	2011-05-27	2012-12-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2530088A1 (en)	2011-05-30	2012-12-05	Klinikum rechts der Isar der Technischen Universität München	Means and methods for diagnosing and treating multiple sclerosis
EP2714742A1 (en)	2011-06-03	2014-04-09	CT Atlantic Ltd.	Magea3 binding antibodies
WO2012163769A1 (en)	2011-06-03	2012-12-06	Ct Atlantic Ltd.	Magea3 binding antibodies
EP2718327A1 (en)	2011-06-06	2014-04-16	Neotope Biosciences Limited	Mcam antagonists and methods of treatment
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
US20140120555A1 (en)	2011-06-20	2014-05-01	Pierre Fabre Medicament	Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EA030777B9 (ru)	2011-06-23	2019-02-28	Байоджен Интернэшнл Нейросайенз Гмбх	Анти-альфа-синуклеинсвязывающие молекулы
DE202011103324U1 (de)	2011-07-12	2012-01-02	Nekonal S.A.R.L.	Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
JP5376095B2 (ja)	2011-08-11	2013-12-25	アステラス製薬株式会社	新規抗ヒトｎｇｆ抗体
EP2743699A4 (en)	2011-08-12	2015-04-08	Nat Inst Infectious Diseases	METHOD FOR TESTING, PREVENTING AND TREATING INFECTIOUS DISEASE ASPERGILLUS FUMIGATUS AND COMPOSITION
EP2741777B1 (en)	2011-08-12	2017-01-18	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
GB201116092D0 (en)	2011-09-16	2011-11-02	Bioceros B V	Antibodies and uses thereof
MY183989A (en)	2011-09-19	2021-03-17	Axon Neuroscience Se	Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
GB2495115A (en) *	2011-09-29	2013-04-03	Oxford Plastic Sys Ltd	Base for supporting temporary fence panels or posts.
TW201329105A (zh)	2011-10-04	2013-07-16	Thr Trustees Of Columbia University In The City Of New York	人類ｎｏｔｃｈ１引誘物
WO2013050441A1 (en)	2011-10-05	2013-04-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US20140248294A1 (en)	2011-10-05	2014-09-04	University Of Bremen	Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055911A1 (en)	2011-10-14	2013-04-18	Dana-Farber Cancer Institute, Inc.	Znf365/zfp365 biomarker predictive of anti-cancer response
CN109456932A (zh)	2011-10-17	2019-03-12	米纳瓦生物技术公司	用于干细胞增殖和诱导的培养基
EP2768971A1 (en)	2011-10-20	2014-08-27	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the detection and the treatment of cardiac remodeling
EP2589609A1 (en)	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigen binding protein and its use as addressing product for the treatment of cancer
US9427464B2 (en)	2011-11-22	2016-08-30	Chiome Bioscience Inc.	Anti-human TROP-2 antibody having an antitumor activity in vivo
US20140328864A1 (en)	2011-11-22	2014-11-06	Inserm (Institut National De La Sente Et De La Recherche Medicale)	Methods and pharmaceutical compositions for reducing airway hyperresponse
JP6082402B2 (ja)	2011-11-28	2017-02-15	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	加齢に伴う機能障害の処置に使用するための薬学的組成物
EP2602621A1 (en)	2011-12-08	2013-06-12	Julius-Maximilians-Universität Würzburg	LASP-1, a novel urinary marker for transitional cell carcinoma detection
ES2827787T3 (es) *	2011-12-13	2021-05-24	Nordic Nanovector Asa	Anticuerpos HH1 anti-CD37 quiméricos terapéuticos
EP2794660A2 (en)	2011-12-23	2014-10-29	Phenoquest AG	Antibodies for the treatment and diagnosis of affective and anxiety disorders
FR2984750B1 (fr)	2011-12-23	2014-01-10	Lfb Biotechnologies	Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
US9957319B2 (en)	2011-12-28	2018-05-01	Immunoqure Ag	Method of isolating human antibodies
SG11201403756PA (en)	2012-01-01	2014-11-27	Qbi Entpr Ltd	Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
JP6602012B2 (ja)	2012-02-10	2019-11-06	シアトルジェネティクスインコーポレーテッド	Ｃｄ３０＋癌の検出と治療
CA2864539C (en)	2012-02-16	2022-06-07	Santarus, Inc.	Antibody formulations
BR112014020666A2 (pt)	2012-02-23	2018-09-25	U3 Pharma Gmbh	usos de um inibidor de her3
EP2821416B1 (en)	2012-02-28	2018-10-03	Astellas Pharma Inc.	Novel anti-human il-23 receptor antibody
HK1206251A1 (en)	2012-03-15	2016-01-08	Janssen Biotech, Inc.	Human anti-cd27 antibodies, methods and uses
US9567392B2 (en)	2012-03-20	2017-02-14	Biogen Ma Inc.	JCV neutralizing antibodies
EP2832857B1 (en)	2012-03-30	2018-01-03	Daiichi Sankyo Company, Limited	Cdr-modified anti-siglec-15 antibody
CA2868965A1 (en)	2012-03-30	2013-10-03	Daiichi Sankyo Company, Limited	Anti-siglec-15 antibody
WO2013150518A1 (en)	2012-04-01	2013-10-10	Rappaport Family Institute For Research In The Medical Sciences	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
CN103382223B (zh)	2012-04-01	2015-06-10	上海益杰生物技术有限公司	针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2013152010A1 (en)	2012-04-02	2013-10-10	Gundersen Lutheran Health System, Inc.	Reagents, methods, and kits for the classification of cancer
CN104334724B (zh)	2012-04-09	2020-09-01	第一三共株式会社	抗-fgfr2抗体
ES2733434T3 (es)	2012-04-27	2019-11-29	Daiichi Sankyo Co Ltd	Anticuerpos anti-ROBO4
US9062120B2 (en)	2012-05-02	2015-06-23	Janssen Biotech, Inc.	Binding proteins having tethered light chains
US9416189B2 (en)	2012-05-11	2016-08-16	Microbial Chemistry Research Foundation	Anti-CXADR antibody
ES2766836T3 (es)	2012-05-15	2020-06-15	Eisai Inc	Métodos para el tratamiento de cáncer gástrico
CN105473723A (zh)	2012-05-18	2016-04-06	宾夕法尼亚大学托管会	亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
WO2013174834A1 (en)	2012-05-22	2013-11-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating focal segmental glomerulosclerosis
KR101937733B1 (ko)	2012-05-24	2019-01-11	마운트게이트 그룹 리미티드	광견병 감염의 방지 및 치료에 관한 조성물 및 방법
JP6382191B2 (ja)	2012-07-13	2018-08-29	ザトラスティーズオブザユニバーシティオブペンシルバニア	Ｃａｒの抗腫瘍活性のための毒性管理
WO2014013005A1 (en)	2012-07-18	2014-01-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing and treating chronic kidney disease (ckd)
EP3539563A1 (en)	2012-07-19	2019-09-18	Redwood Bioscience, Inc.	Antibody specific for cd22 and methods of use thereof
WO2014021339A1 (ja)	2012-07-30	2014-02-06	国立大学法人名古屋大学	ヒトミッドカインに対するモノクローナル抗体
AU2013306390B2 (en)	2012-08-24	2018-07-05	The Regents Of The University Of California	Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
TWI595007B (zh)	2012-09-10	2017-08-11	Neotope Biosciences Ltd	抗ｍｃａｍ抗體及相關使用方法
SG11201501924UA (en)	2012-09-13	2015-05-28	Chugai Pharmaceutical Co Ltd	Gene knock-in non-human animal
EP2711016A1 (en)	2012-09-21	2014-03-26	Covagen AG	Novel IL-17A binding molecules and medical uses thereof
DK2905335T3 (en)	2012-10-03	2018-03-12	Chiome Bioscience Inc	Anti-human dlk-1 antibody with anti-tumor activity in vivo
CA2886120A1 (en)	2012-10-08	2014-04-17	St. Jude Children's Research Hospital	Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US10195288B2 (en)	2012-10-11	2019-02-05	Daiichi Sankyo Company, Limited	Antibody-drug conjugate
DE102012020496A1 (de)	2012-10-18	2014-04-24	Charité - Universitätsmedizin Berlin	Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2014061277A1 (ja)	2012-10-19	2014-04-24	第一三共株式会社	親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
EP2911681A1 (en)	2012-10-26	2015-09-02	Institut National de la Santé et de la Recherche Médicale (INSERM)	Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
JP6694712B2 (ja)	2012-11-01	2020-05-20	マックス−デルブルック−セントラムフアーモレキュラーレメデジン	Ｃｄ２６９（ｂｃｍａ）に対する抗体
CA2890265C (en)	2012-11-05	2023-01-17	Pierre Fabre Medicament	Antigen binding proteins and their use as addressing product for the treatment of cancer
WO2014072416A1 (en)	2012-11-08	2014-05-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of bone metastases
AR093445A1 (es)	2012-11-14	2015-06-10	Regeneron Pharma	Metodos para tratar el cancer de ovario con antagonistas de dll4
SI2928923T1 (sl)	2012-12-10	2020-03-31	Biogen Ma Inc.	Protitelesa proti antigenu 2 dendritičnih celic v krvi in njihova uporaba
US20160185847A1 (en)	2012-12-17	2016-06-30	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
US10024844B2 (en)	2012-12-20	2018-07-17	Hospital For Special Surgery	Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
EP3792278A3 (en)	2012-12-21	2021-05-26	Biogen MA Inc.	Human anti-tau antibodies
EP3517545A1 (en)	2012-12-31	2019-07-31	Neurimmune Holding AG	Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
EP2752426A1 (en)	2013-01-03	2014-07-09	Covagen AG	Human serum albumin binding compounds and fusion proteins thereof
US9550825B2 (en)	2013-01-28	2017-01-24	Evec Inc.	Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
US20150377888A1 (en)	2013-02-01	2015-12-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
JP6357113B2 (ja)	2013-02-08	2018-07-11	株式会社医学生物学研究所	ヒトｎｒｇ１タンパク質に対する抗体
AU2013378628A1 (en)	2013-02-15	2015-06-11	Esbatech - A Novartis Company Llc	Acceptor framework for CDR grafting
HK1219485A1 (zh)	2013-02-20	2017-04-07	Esbatech - A Novartis Company Llc	用於cdr移植的受体框架
FR3004184B1 (fr)	2013-02-26	2016-03-18	Agronomique Inst Nat Rech	Anticorps anti-gluten desamide et utilisations.
WO2014133093A1 (ja)	2013-02-28	2014-09-04	独立行政法人国立がん研究センター	不溶性フィブリンに対する抗体
JP6218088B2 (ja)	2013-03-08	2017-11-01	国立大学法人大阪大学	ペリオスチンのＥｘｏｎ−２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
BR112015022587A2 (pt)	2013-03-13	2017-10-24	Eleven Biotherapeutics Inc	formulações de citocina quimérica para entrega ocular
US10023608B1 (en)	2013-03-13	2018-07-17	Amgen Inc.	Protein purification methods to remove impurities
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2014151917A1 (en)	2013-03-14	2014-09-25	Ffe Therapeutics Llc	Compositions and methods for treating angiogenesis-related disorders
WO2014143739A2 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
KR20150128796A (ko)	2013-03-15	2015-11-18	바이오젠 엠에이 인코포레이티드	항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방
WO2014144466A1 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
DK2976361T3 (en)	2013-03-18	2018-10-01	Biocerox Prod Bv	HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
WO2014165524A2 (en)	2013-04-01	2014-10-09	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with avb8 integrin
WO2014174596A1 (ja)	2013-04-23	2014-10-30	株式会社医学生物学研究所	ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US9717648B2 (en)	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN107460201A (zh)	2013-05-08	2017-12-12	科济生物医药（上海）有限公司	编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
EP3159695A3 (en)	2013-06-20	2017-07-05	The Trustees of The University of Pennsylvania	Methods for diagnosing pancreatic cancer
CN105518025B (zh)	2013-07-03	2020-12-08	因美诺克股份公司	人抗IFN-α抗体
JP6450381B2 (ja)	2013-07-05	2019-01-09	ユニバーシティオブワシントンスルーイッツセンターフォーコマーシャリゼーション	がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
US20160176943A1 (en)	2013-07-05	2016-06-23	Inserm (Insititut National De La Sante Et De La Recherche Medicale)	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
ES2730978T3 (es)	2013-08-09	2019-11-13	Astellas Pharma Inc	Anticuerpo anti-receptor de TSLP humana nuevo
WO2015036956A1 (en)	2013-09-12	2015-03-19	Institut National De La Sante Et De La Recherche Medicale	Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
AU2014322988B2 (en)	2013-09-20	2018-12-06	Westfaelische Wilhelms-Universitaet Muenster	Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
CN105764923A (zh)	2013-09-24	2016-07-13	范因斯坦医学研究院	对可冷诱导的rna结合蛋白活性进行抑制的肽
ES2894333T3 (es)	2013-09-26	2022-02-14	Beth Israel Deaconess Medical Ct Inc	Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
WO2015046505A1 (ja)	2013-09-30	2015-04-02	第一三共株式会社	抗ｌｐｓｏ１１抗体
ES2714708T3 (es)	2013-10-01	2019-05-29	Mayo Found Medical Education & Res	Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
TWI664977B (zh)	2013-10-08	2019-07-11	第一三共股份有限公司	抗ｆｇｆｒ２抗體及其與其他藥劑之組合
JPWO2015068781A1 (ja)	2013-11-06	2017-03-09	国立大学法人大阪大学	インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
EP3065774B1 (en)	2013-11-06	2021-05-26	Janssen Biotech, Inc.	Anti-ccl17 antibodies
EP3068419A1 (en)	2013-11-15	2016-09-21	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of pancreatic cancers
WO2015082446A1 (en)	2013-12-02	2015-06-11	F. Hoffmann-La Roche Ag	Treatment of cancer using an anti-cdcp1 antibody and a taxane
US10294301B2 (en)	2013-12-24	2019-05-21	Astellas Pharma Inc.	Anti-human BDCA-2 antibody
CN111228510B (zh)	2013-12-25	2024-06-18	第一三共株式会社	抗trop2抗体-药物偶联物
ES2902835T3 (es)	2014-01-09	2022-03-30	Hadasit Med Res Service	Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
EP3094652B1 (en)	2014-01-13	2021-09-29	Baylor Research Institute	Novel vaccines against hpv and hpv-related diseases
CN104774264B (zh)	2014-01-15	2018-09-14	上海易乐生物技术有限公司	抗人proBDNF单克隆抗体及其在疼痛中的作用
EP3973995A1 (en)	2014-01-31	2022-03-30	Daiichi Sankyo Company, Limited	Anti-her2 antibody-drug conjugate
JP6666848B2 (ja)	2014-02-18	2020-03-18	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｎｒｐ−１／ｏｂｒ複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物
WO2015124570A1 (en)	2014-02-18	2015-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP3415160B1 (en)	2014-03-04	2021-08-18	Klinikum der Universität München	Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2015140351A1 (en)	2014-03-21	2015-09-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing myelination
EP3122768A2 (en)	2014-03-27	2017-02-01	Yeda Research and Development Co. Ltd.	T-cell receptor cdr3 peptides and antibodies
TWI874262B (zh)	2014-04-10	2025-02-21	日商第一三共股份有限公司	抗her3抗體-藥物結合物之用途
EP3132053B1 (en)	2014-04-15	2020-09-30	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Differential diagnosis of eczema and psoriasis
CA2944903A1 (en)	2014-04-24	2015-10-29	Dana-Farber Cancer Institute, Inc.	Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
MA39909B1 (fr)	2014-04-25	2019-05-31	Pf Medicament	Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
DK3134438T3 (da)	2014-04-25	2020-12-07	Pf Medicament	IGF-1R-antistof og anvendelse heraf som adresseringsvehikel til behandling af cancer
WO2015162293A1 (en)	2014-04-25	2015-10-29	Pierre Fabre Medicament	Antibody-drug-conjugate and its use for the treatment of cancer
US11427647B2 (en)	2014-04-27	2022-08-30	Famewave Ltd.	Polynucleotides encoding humanized antibodies against CEACAM1
MD20160130A2 (ro)	2014-04-27	2017-04-30	Ccam Biotherapeutics Ltd.	Anticorpi umanizaţi contra CEACAM1
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
EP3598980B1 (en)	2014-06-26	2026-01-28	Yale University	Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2016011383A1 (en)	2014-07-17	2016-01-21	The Trustees Of The University Of Pennsylvania	Methods for using exosomes to monitor transplanted organ status
CN105315375B (zh)	2014-07-17	2021-04-23	恺兴生命科技(上海)有限公司	靶向cld18a2的t淋巴细胞及其制备方法和应用
US10517875B2 (en)	2014-07-23	2019-12-31	Mayo Foundation for Medical Engineering and Research	Targeting DNA-PKcs and B7-H1 to treat cancer
AU2015295441B2 (en)	2014-07-29	2020-05-14	Neurimmune Holding Ag	Human-derived anti-huntingtin (HTT) antibodies and uses thereof
BR112017006598A2 (en)	2014-09-30	2018-04-17	Neurimmune Holding Ag	human derived antidipeptide repeat antibody (dprs)
CA2963470A1 (en)	2014-10-03	2016-04-07	Massachusetts Institute Of Technology	Antibodies that bind ebola glycoprotein and uses thereof
US20170248603A1 (en)	2014-10-06	2017-08-31	Dana-Farber Cancer Institute, Inc.	Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
JP6941561B2 (ja)	2014-10-09	2021-09-29	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
WO2016081835A2 (en)	2014-11-21	2016-05-26	University Of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
US20170319661A1 (en)	2014-12-03	2017-11-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
EP3256148A1 (en)	2015-02-12	2017-12-20	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
WO2016144673A1 (en)	2015-03-06	2016-09-15	Dana-Farber Cancer Institute, Inc.	Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3067062A1 (en)	2015-03-13	2016-09-14	Ipsen Pharma S.A.S.	Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
AU2016232749B2 (en)	2015-03-18	2021-09-23	The Johns Hopkins University	Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
ES2805743T3 (es)	2015-03-24	2021-02-15	Inst Nat Sante Rech Med	Método y composición farmacéutica para uso en el tratamiento de la diabetes
WO2016156557A1 (en)	2015-04-03	2016-10-06	Alienor Farma	Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
WO2016166110A1 (en)	2015-04-13	2016-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
WO2016170027A1 (en)	2015-04-22	2016-10-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
EP3303389A1 (en)	2015-06-01	2018-04-11	Medigene Immunotherapies GmbH	T-cell receptor specific antibodies
EP3303392B1 (en)	2015-06-01	2020-08-05	Medigene Immunotherapies GmbH	Method for generating antibodies against t cell receptor
CA2987857A1 (en)	2015-06-01	2016-12-08	Medigene Immunotherapies Gmbh	T cell receptor library
RU2748992C2 (ru)	2015-06-19	2021-06-02	Центурион Байофарма Корпорейшн	Системы доставки для контролируемого высвобождения лекарственного средства
AU2016282986A1 (en)	2015-06-26	2018-02-01	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
ES2938186T3 (es)	2015-06-29	2023-04-05	Daiichi Sankyo Co Ltd	Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco
KR20180030917A (ko)	2015-08-05	2018-03-26	얀센 바이오테크 인코포레이티드	항-cd154 항체 및 그의 사용 방법
WO2017044866A2 (en)	2015-09-11	2017-03-16	Nascent Biotech, Inc.	Enhanced delivery of drugs to the brain
US11078251B2 (en)	2015-09-18	2021-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
DK3353196T5 (da)	2015-09-22	2024-09-30	Inst Nat Sante Rech Med	Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
SG10201912570UA (en)	2015-09-24	2020-02-27	Daiichi Sankyo Co Ltd	Anti-garp antibody
EA037882B1 (ru)	2015-09-30	2021-05-31	Янссен Байотек, Инк.	Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EP3360961B1 (en)	2015-10-08	2023-11-22	National University Corporation Tokai National Higher Education and Research System	Method for preparing genetically-modified t cells which express chimeric antigen receptor
EP3362093A4 (en)	2015-10-13	2019-05-08	Technion Research & Development Foundation Limited	HEPARANASE-NEUTRALIZING MONOCLONAL ANTIBODIES
US20180305458A1 (en)	2015-10-16	2018-10-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US10858423B2 (en)	2015-10-26	2020-12-08	Pierre Fabre Medicament	Composition for the treatment of IGF-1R expressing cancer
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
ITUB20155272A1 (it)	2015-11-02	2017-05-02	Scuola Normale Superiore	Intracellular antibody
WO2017079215A1 (en)	2015-11-03	2017-05-11	Glycomimetics, Inc.	Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
JP2019500893A (ja)	2015-11-03	2019-01-17	ヤンセンバイオテツク，インコーポレーテツド	Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
ITUB20155097A1 (it)	2015-11-05	2017-05-05	Biouniversa Srl	Anticorpi umanizzati anti-BAG3
WO2017097889A1 (en)	2015-12-10	2017-06-15	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
KR20180087430A (ko)	2015-12-17	2018-08-01	얀센 바이오테크 인코포레이티드	Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
ES2863733T3 (es)	2015-12-23	2021-10-11	Medigene Immunotherapies Gmbh	Generación novedosa de TCR específicos de antígeno
CA3009740A1 (en)	2015-12-31	2017-07-06	Progastrine Et Cancers S.A R.L.	Compositions and methods for detecting and treating gastric cancer
EP3848709B1 (en)	2015-12-31	2024-12-04	ECS-Progastrin SA	Methods for detecting esophageal cancer
CN108780091A (zh)	2015-12-31	2018-11-09	普莱戈斯瑞恩癌症有限责任公司	用于检测和治疗卵巢癌的组合物和方法
EP3202788A1 (en)	2016-02-05	2017-08-09	MediaPharma S.r.l.	Endosialin-binding antibody
EP3205663A1 (en)	2016-02-15	2017-08-16	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Means and methods for inhibiting gene expression
ES2930077T3 (es)	2016-02-15	2022-12-07	Inst Nat Sante Rech Med	Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria
WO2017149538A1 (en)	2016-03-01	2017-09-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to human poliovirus receptor (pvr)
WO2017153432A1 (en)	2016-03-07	2017-09-14	Pierre Fabre Medicament	A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
US11921116B2 (en)	2016-03-09	2024-03-05	Memorial Sloan Kettering Cancer Center	Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
JP6903680B2 (ja)	2016-03-15	2021-07-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (en)	2016-03-21	2019-01-30	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods for diagnosis and treatment of solar lentigo
US10822416B2 (en)	2016-03-23	2020-11-03	Mabspace Biosciences (Suzhou) Co., Ltd	Anti-PD-L1 antibodies
LT3436461T (lt)	2016-03-28	2024-03-12	Incyte Corporation	Pirolotriazino junginiai kaip tam inhibitoriai
ITUA20162242A1 (it)	2016-04-01	2017-10-01	St Biochimico Italiano Giovanni Lorenzini Spa	Un nuovo anticorpo anti-erbb2
LT3445785T (lt)	2016-04-18	2022-10-10	Faron Pharmaceuticals Oy	Humanizuoti anti clever-1 antikūnai ir jų naudojimas
US11406686B2 (en)	2016-05-03	2022-08-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of tissue lesions with CCR2 agonists
US11384140B2 (en)	2016-05-11	2022-07-12	Amgen Inc.	Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
EP3458093A1 (de)	2016-05-20	2019-03-27	Christoph Karl	Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien
WO2017202814A1 (en)	2016-05-24	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
WO2017202813A1 (en)	2016-05-24	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
SG10202012157QA (en)	2016-06-07	2021-01-28	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Chimeric antigen receptor and car-t cells that bind bcma
GB201610198D0 (en)	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
AU2017292172A1 (en)	2016-07-06	2019-01-03	Prothena Biosciences Limited	Assay for detecting total and S129 phosphorylated alpha-synuclein
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3487880A1 (en)	2016-07-25	2019-05-29	Biogen MA Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
EP3491387A1 (en)	2016-07-28	2019-06-05	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods of treatement of cancer disease by targetting tumor associated macrophage
SG11201900744SA (en)	2016-08-12	2019-02-27	Janssen Biotech Inc	Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
CA3033661A1 (en)	2016-08-12	2018-02-15	Janssen Biotech, Inc.	Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018057618A1 (en)	2016-09-20	2018-03-29	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
EP3524267A4 (en)	2016-10-07	2020-06-10	Daiichi Sankyo Company, Limited	THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTERING ANTI-HER2 ANTIBODIES / DRUG CONJUGATE
WO2018070390A1 (ja)	2016-10-12	2018-04-19	第一三共株式会社	抗ｒｏｂｏ４抗体と他剤を含む組成物
EP3525815A2 (en)	2016-10-13	2019-08-21	Massachusetts Institute of Technology	Antibodies that bind zika virus envelope protein and uses thereof
IT201600111877A1 (it)	2016-11-07	2018-05-07	Biouniversa Srl	Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
RU2767793C2 (ru)	2016-11-18	2022-03-21	Астеллас Фарма Инк.	НОВЫЙ Fab-ФРАГМЕНТ АНТИТЕЛА ПРОТИВ MUC1 ЧЕЛОВЕКА
EP3552626A4 (en)	2016-12-12	2020-06-10	Daiichi Sankyo Company, Limited	ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
RU2754058C2 (ru)	2016-12-13	2021-08-26	Астеллас Фарма Инк.	Антитело к cd73 человека
EP3555128B1 (en)	2016-12-15	2023-12-27	The National Institute for Biotechnology in the Negev Ltd.	Anti-pcna monoclonal antibodies and use thereof
CN118126180A (zh)	2016-12-22	2024-06-04	第一三共株式会社	抗cd3抗体和包含所述抗体的分子
US20180179490A1 (en)	2016-12-27	2018-06-28	Miltenyi Biotec Gmbh	CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
US11773182B2 (en)	2017-01-05	2023-10-03	The Johns Hopkins University	Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
BR112019012847A2 (pt)	2017-01-17	2019-12-10	Daiichi Sankyo Co Ltd	anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
WO2018140510A1 (en)	2017-01-25	2018-08-02	Biogen Ma Inc.	Compositions and methods for treatment of stroke and other cns disorders
CN110462038A (zh)	2017-02-07	2019-11-15	第一三共株式会社	抗gprc5d抗体和包含所述抗体的分子
EP3363459A1 (en)	2017-02-17	2018-08-22	Alexander Klimka	Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
WO2018157169A1 (en)	2017-02-27	2018-08-30	Caerus Therapeutics, Inc.	Antibody constructs and methods of treating cancer
KR20190120764A (ko)	2017-02-28	2019-10-24	갓코 호진 긴키 다이가쿠	항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
EP3596126A4 (en)	2017-03-15	2021-03-03	Tsinghua University	NOVEL ANTI-TRKB ANTIBODIES
JOP20180021A1 (ar)	2017-03-16	2019-01-30	Janssen Biotech Inc	الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
TWI782000B (zh)	2017-03-30	2022-11-01	日商第一三共股份有限公司	抗ｇｐｒ２０抗體、其製造方法及其應用
BR112019020414A2 (pt)	2017-03-30	2020-06-09	Progastrine Et Cancers S.À R.L.	composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
KR102616819B1 (ko)	2017-03-30	2023-12-21	프로가스트린 에 캔서스 에스.에이 알.엘.	폐암을 치료하기 위한 조성물 및 방법
US10722589B2 (en)	2017-04-03	2020-07-28	Covagen Ag	FGFR3 binding molecules
WO2018185516A1 (en)	2017-04-05	2018-10-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189335A1 (en)	2017-04-13	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en)	2017-04-14	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancer
CN111201034A (zh)	2017-05-11	2020-05-26	西托戴恩股份有限公司	涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
TW202532104A (zh)	2017-05-15	2025-08-16	日商第一三共股份有限公司	抗體－藥物結合物及其用途
WO2018226580A2 (en)	2017-06-05	2018-12-13	Janssen Biotech, Inc.	Antibodies that specifically bind pd-1 and methods of use
US11820822B2 (en)	2017-06-06	2023-11-21	Dana-Farber Cancer Institute, Inc.	Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US20200199207A1 (en)	2017-06-23	2020-06-25	Mabylon Ag	Anti-allergen antibodies
US20210145828A1 (en)	2017-06-29	2021-05-20	Rutgers, The State University Of New Jersey	Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
CN110913905A (zh)	2017-06-30	2020-03-24	国立大学法人北海道大学	不产生生长障碍的小儿骨质疏松症治疗药
TWI795415B (zh)	2017-07-07	2023-03-11	日商安斯泰來製藥股份有限公司	新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
BR112020001255A2 (pt)	2017-07-21	2020-07-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	composições imunogênicas de neisseria meningitidis
TWI818916B (zh)	2017-07-27	2023-10-21	日商第一三共股份有限公司	抗ｃｄ１４７抗體、及其用途與製造方法
WO2019020734A1 (en)	2017-07-28	2019-01-31	Biouniversa S.R.L.	ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES
JP6889328B2 (ja)	2017-07-31	2021-06-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	三次元構造に基づくヒト化方法
EP3444272A1 (en)	2017-08-17	2019-02-20	International-Drug-Development-Biotech	Treatment of ck8 positive cancers in relation with k-ras gene status
US20210128741A1 (en)	2017-08-23	2021-05-06	Daiichi Sankyo Company, Limited	Antibody-drug conjugate preparation and lyophilization for same
US11643468B2 (en)	2017-08-23	2023-05-09	Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-Gemeinschaft	Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders
JP7366745B2 (ja)	2017-08-31	2023-10-23	第一三共株式会社	抗体－薬物コンジュゲートの改良製造方法
CN117838881A (zh)	2017-08-31	2024-04-09	第一三共株式会社	制备抗体-药物缀合物的新方法
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV
CN111386273B (zh)	2017-09-27	2024-06-14	因赛特公司	可用作tam抑制剂的吡咯并三嗪衍生物的盐
TWI820044B (zh)	2017-09-29	2023-11-01	日商第一三共股份有限公司	抗體－吡咯并苯二氮呯衍生物複合體
JPWO2019069561A1 (ja)	2017-10-03	2020-10-22	公益財団法人東京都医学総合研究所	インフルエンザに対する医薬
JP7384668B2 (ja)	2017-10-05	2023-11-21	第一三共株式会社	細胞傷害性ｔ細胞枯渇用組成物
KR101966362B1 (ko) *	2017-10-20	2019-04-05	주식회사 녹십자	항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019094595A2 (en)	2017-11-09	2019-05-16	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
CN111712511B (zh)	2017-11-30	2024-07-16	拉德克斯公司	澳瑞他汀e衍生物的白蛋白结合产物
BR112020010989A2 (pt)	2017-11-30	2020-11-17	Centurion Biopharma Corporation	sistemas de distribuição de droga à base de maitansinoide
WO2019106126A1 (en)	2017-12-01	2019-06-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mdm2 modulators for the diagnosis and treatment of liposarcoma
CA3084687C (en)	2017-12-05	2024-01-02	Progastrine Et Cancers S.A R.L.	Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
WO2019121872A1 (en)	2017-12-20	2019-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of liver cancer
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
TW201940881A (zh)	2018-01-26	2019-10-16	瑞士商Ｅｃｓ前胃泌激素公司	在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3752252A4 (en)	2018-02-12	2021-11-17	Hadasit Medical Research Services and Development Ltd.	MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER TREATMENT
WO2019158512A1 (en)	2018-02-13	2019-08-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prognosis and the treatment of glioblastoma
US20200400675A1 (en)	2018-02-27	2020-12-24	Ecs-Progastrin Sa	Progastrin as a biomarker for immunotherapy
KR20200139153A (ko)	2018-02-27	2020-12-11	인사이트 코포레이션	A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
US20210032334A1 (en)	2018-02-28	2021-02-04	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
BR112020018112A2 (pt)	2018-03-05	2020-12-22	Janssen Pharmaceutica Nv	Anticorpos anti-phf-tau e usos dos mesmos
CA3093205A1 (en)	2018-03-05	2019-09-12	Saitama Medical University	Pharmaceutical composition for treating or preventing heterotopic ossification
CN119770648A (zh)	2018-03-09	2025-04-08	克莱格医学有限公司	用于治疗肿瘤的方法和组合物
CN112566642B (zh)	2018-03-14	2025-01-17	纪念斯隆凯特琳癌症中心	抗聚唾液酸抗体及其用途
US20210047696A1 (en)	2018-03-28	2021-02-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
US12103972B2 (en)	2018-04-06	2024-10-01	Dana-Farber Cancer Institute, Inc.	KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
EP3775908A1 (en)	2018-04-13	2021-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
EP3781590A1 (en)	2018-04-20	2021-02-24	Medizinische Hochschule Hannover	Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
WO2019207066A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for the treatment of sjögren's syndrome
WO2019211369A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
KR102892725B1 (ko)	2018-05-09	2025-12-01	이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디.	인간 넥틴4에 특이적인 항체
BR112020023041A2 (pt)	2018-05-11	2021-02-09	Astellas Pharma Inc.	ácido nucleico para tratar alergia a ácaros
US20210163549A1 (en)	2018-05-11	2021-06-03	Astellas Pharma Inc.	Nucleic acid for treating crustacean allergy
MX2020012351A (es)	2018-05-17	2021-01-29	Astellas Pharma Inc	Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
JP7391046B2 (ja)	2018-05-18	2023-12-04	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN112513085B (zh)	2018-05-24	2024-06-18	詹森生物科技公司	Psma结合剂及其用途
PE20210634A1 (es)	2018-05-24	2021-03-23	Janssen Biotech Inc	Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
EP3802608B1 (en)	2018-05-24	2025-04-30	Janssen Biotech, Inc.	Anti-cd3 antibodies and uses thereof
SG11202011243XA (en)	2018-05-28	2020-12-30	Daiichi Sankyo Co Ltd	Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AU2019279206B2 (en)	2018-05-31	2025-06-26	Daiichi Sankyo Company, Limited	Anti-human TLR7 antibody
BR112020024351A2 (pt)	2018-06-01	2021-02-23	Novartis Ag	moléculas de ligação contra bcma e usos das mesmas
US12037398B2 (en)	2018-06-04	2024-07-16	Biogen Ma Inc.	Anti-VLA-4 antibodies having reduced effector function
WO2019234099A1 (en)	2018-06-06	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en)	2018-06-08	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
AU2019288276B2 (en)	2018-06-20	2026-02-12	Incyte Corporation	Anti-PD-1 antibodies and uses thereof
WO2019244107A1 (en)	2018-06-21	2019-12-26	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
CN113164398B (zh)	2018-06-29	2023-11-03	因赛特公司	Axl/mer抑制剂的制剂
WO2020007898A1 (en)	2018-07-04	2020-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating brain injury or neurodegenerative disease
CN117304191A (zh)	2018-07-05	2023-12-29	因赛特公司	作为a2a/a2b抑制剂的稠合吡嗪衍生物
WO2020022363A1 (ja)	2018-07-25	2020-01-30	第一三共株式会社	抗体－薬物コンジュゲートの効果的な製造方法
AU2019311596A1 (en)	2018-07-27	2021-01-28	Daiichi Sankyo Company, Limited	Protein recognizing drug moiety of antibody-drug conjugate
US20210308170A1 (en)	2018-07-27	2021-10-07	Osaka University	Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
WO2020027100A1 (ja)	2018-07-31	2020-02-06	第一三共株式会社	抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
KR20210042120A (ko)	2018-08-06	2021-04-16	다이이찌 산쿄 가부시키가이샤	항체-약물 콘주게이트와 튜불린 저해제의 조합
IL315138A (en)	2018-09-06	2024-10-01	Daiichi Sankyo Co Ltd	Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
EP3854418A4 (en)	2018-09-20	2022-07-27	Daiichi Sankyo Company, Limited	TREATMENT OF HER3 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE
WO2020059847A1 (ja)	2018-09-21	2020-03-26	国立大学法人東京医科歯科大学	ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
AU2019350536A1 (en)	2018-09-27	2021-05-06	Pierre Fabre Medicament	Sulfomaleimide-based linkers and corresponding conjugates
WO2020065096A1 (en)	2018-09-28	2020-04-02	Pierre Fabre Medicament	New immunocytokines for the treatment of cancer
SG11202103670XA (en)	2018-10-10	2021-05-28	Astellas Pharma Inc	Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
EP3867269A1 (en)	2018-10-18	2021-08-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
EP3873500A4 (en)	2018-10-31	2023-01-11	Mayo Foundation for Medical Education and Research	METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
MY204672A (en)	2018-10-31	2024-09-09	Astellas Pharma Inc	Anti-human fn14 antibody
EP3873540A4 (en)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3880706A1 (en)	2018-11-12	2021-09-22	MediaPharma S.r.l.	Bispecific antibodies directed against human 90k and either endosialin or her3
BR112021009251A2 (pt)	2018-11-14	2021-08-10	Daiichi Sankyo Company, Limited	conjugado anticorpo-fármaco, anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para produção de um anticorpo com glicano remodelado, de um conjugado anticorpo-fármaco, do anticorpo ou um fragmento funcional do mesmo e para tratamento de um tumor.
JP2022513082A (ja)	2018-11-19	2022-02-07	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
EA202191641A1 (ru)	2018-12-11	2021-09-13	Дайити Санкио Компани, Лимитед	Комбинация конъюгата антитело-лекарственное средство с ингибитором parp
EP3897854A2 (en)	2018-12-21	2021-10-27	Aim Immunotech Inc.	Compositions and methods for cancer therapy
SG11202106635WA (en)	2018-12-21	2021-07-29	Daiichi Sankyo Co Ltd	Combination of antibody-drug conjugate and kinase inhibitor
SG11202107400QA (en)	2019-01-07	2021-08-30	Astellas Pharma Inc	Conjugate comprising ligand and ceacam5 antibody fab fragment
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
CA3125962A1 (en)	2019-01-13	2020-07-16	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to human nectin-2
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP3917515A1 (en)	2019-01-29	2021-12-08	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Treating the causative agent in adhesiogenesis
CN113795513B (zh)	2019-02-13	2025-02-18	布里格姆妇女医院	抗外周淋巴结地址素抗体及其用途
WO2020178193A1 (en)	2019-03-01	2020-09-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method of treatment of sarcoidosis
WO2020185763A1 (en)	2019-03-11	2020-09-17	Memorial Sloan Kettering Cancer Center	Cd22 antibodies and methods of using the same
EP3942026A1 (en)	2019-03-22	2022-01-26	Université de Paris	New inhibitors of lrrk2/pp1 interaction
US20220177601A1 (en)	2019-03-25	2022-06-09	Daiichi Sankyo Company, Limited	Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3950061A4 (en)	2019-03-25	2022-11-16	Daiichi Sankyo Company, Limited	ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
AU2020247119A1 (en)	2019-03-25	2021-09-23	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Enhancement of cytolytic T-cell activity by inhibiting EBAG9
KR20210143839A (ko)	2019-03-27	2021-11-29	다이이찌 산쿄 가부시키가이샤	항체-피롤로벤조디아제핀 유도체 콘주게이트와 parp 저해제의 조합
WO2020204033A1 (ja)	2019-04-01	2020-10-08	株式会社カイオム・バイオサイエンス	がん治療用医薬
BR112021019701A2 (pt)	2019-04-02	2021-12-14	Kenjockety Biotechnology Inc	Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
MA55717A (fr)	2019-04-19	2022-02-23	Janssen Biotech Inc	Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
WO2020223445A1 (en)	2019-04-30	2020-11-05	Senti Biosciences, Inc.	Chimeric receptors and methods of use thereof
US20220289854A1 (en)	2019-04-30	2022-09-15	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP3969569A1 (en)	2019-05-14	2022-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
WO2020243346A1 (en)	2019-05-28	2020-12-03	The General Hospital Corporation	Apoe antibodies, fusion proteins and uses thereof
CN113939318A (zh)	2019-05-29	2022-01-14	第一三共株式会社	抗体-药物缀合物的制剂
CA3144324A1 (en)	2019-06-24	2020-12-30	Novartis Ag	Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
JP7668013B2 (ja)	2019-07-26	2025-04-24	学校法人埼玉医科大学	Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
BR112022001368A2 (pt)	2019-07-26	2022-05-24	Janssen Biotech Inc	Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
WO2021019706A1 (ja)	2019-07-31	2021-02-04	国立大学法人信州大学	Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
JP2022543062A (ja)	2019-08-01	2022-10-07	インサイト・コーポレイション	Ｉｄｏ阻害剤の投与レジメン
EP4007603A1 (en)	2019-08-02	2022-06-08	CytoDyn Inc.	Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
MX2022001841A (es)	2019-08-12	2022-08-17	Biond Biologics Ltd	Anticuerpos contra ilt2 y uso de los mismos.
EP3792632A1 (en)	2019-09-16	2021-03-17	Vito NV	Immunotherapy markers
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
EP4034160A1 (en)	2019-09-27	2022-08-03	Janssen Biotech, Inc.	Anti-ceacam antibodies and uses thereof
US20220290151A1 (en)	2019-09-27	2022-09-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of müllerian inhibiting substance inhibitors for treating cancer
EP4049675A4 (en)	2019-10-25	2023-11-22	Daiichi Sankyo Company, Limited	COMBINATION OF ANTI-GARP ANTIBODIES AND IMMUNE REGULATOR
PH12022551166A1 (en)	2019-11-15	2023-10-02	Pliant Therapeutics Inc	Compositions and methods for activation of integrins
BR112022009598A2 (pt)	2019-11-18	2022-08-16	Janssen Biotech Inc	Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
EP4073123A4 (en) *	2019-12-10	2024-01-10	CCOA Therapeutics Inc.	HUMANIZED ANTIBODIES IB ALPHA (GPIBALPHA) ANTIBODIES
JP7758672B2 (ja)	2019-12-20	2025-10-22	ノヴァロックバイオセラピューティクス，リミテッド	抗インターロイキン－２３ｐ１９抗体およびそれの使用方法
WO2021138512A1 (en)	2020-01-03	2021-07-08	Incyte Corporation	Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021140173A1 (en)	2020-01-10	2021-07-15	Biouniversa S.R.L.	Methods and uses for treating fibrotic solid tumors with bags inhibitors
US20230075965A1 (en)	2020-01-24	2023-03-09	Constantine S. Mitsiades	Uses of biomarkers for improving immunotherapy
EP4100525A1 (en)	2020-02-05	2022-12-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods of treatment of cancer disease by targeting an epigenetic factor
TWI900527B (zh)	2020-02-12	2025-10-11	比利時商健生藥品公司	用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
CA3173521A1 (en)	2020-02-28	2021-09-02	The Brigham And Women's Hospital, Inc.	Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
KR20220149579A (ko)	2020-03-03	2022-11-08	액티브 바이오테크 에이비	조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
WO2021178779A1 (en)	2020-03-06	2021-09-10	Incyte Corporation	Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN115209921B (zh)	2020-03-06	2025-06-24	第一三共株式会社	包含环状二核苷酸衍生物的抗体药物偶联物
US11896619B2 (en)	2020-03-10	2024-02-13	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of NPM1c-positive cancer
JP2023517660A (ja)	2020-03-13	2023-04-26	ヤンセンバイオテツク，インコーポレーテツド	シグレック３／ｃｄ３３に結合させるための材料及び方法
WO2021200131A1 (ja)	2020-03-30	2021-10-07	国立研究開発法人国立がん研究センター	抗体薬物複合体
US11045546B1 (en)	2020-03-30	2021-06-29	Cytodyn Inc.	Methods of treating coronavirus infection
EP3889183A1 (en)	2020-04-01	2021-10-06	Pierre Fabre Medicament	A protein complex comprising an immunocytokine
IL297104A (en)	2020-04-06	2025-01-01	Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd	Antibodies to NKP46 and their constructs for the treatment of cancer and infections
US20230174670A1 (en)	2020-05-14	2023-06-08	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
US20230192879A1 (en)	2020-05-19	2023-06-22	Institut Curie	Methods for the diagnosis and treatment of cytokine release syndrome
CN116133684B (zh)	2020-05-27	2025-07-18	阿里亚利斯治疗公司	抗人nr1抗体衍生物
PH12022500023A1 (en)	2020-05-27	2024-03-11	Janssen Biotech Inc	Proteins comprising cd3 antigen binding domains and uses thereof
AU2021283080A1 (en)	2020-06-04	2022-12-15	William Robert ARATHOON	ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN116615248A (zh)	2020-06-24	2023-08-18	阿斯利康(英国)有限公司	抗体-药物缀合物和cdk9抑制剂的组合
EP4171650A1 (en)	2020-06-24	2023-05-03	AstraZeneca UK Limited	Combination of antibody-drug conjugate and atr inhibitor
WO2021260582A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260583A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and dna-pk inhibitor
CN116194109A (zh)	2020-06-24	2023-05-30	阿斯利康(英国)有限公司	抗体-药物缀合物和atm抑制剂的组合
EP4171527A1 (en)	2020-06-25	2023-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of treatment and diagnostic of pathological conditions associated with intense stress
JP2023533707A (ja)	2020-07-06	2023-08-04	テクニオンリサーチアンドディベロップメントファウンデーションリミテッド	ヘパラナーゼ中和ａ５４モノクローナル抗体
EP4175664A2 (en)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	Prostate neoantigens and their uses
CA3186205A1 (en)	2020-07-17	2022-01-20	Daiichi Sankyo Company, Limited	Method for producing antibody-drug conjugate
KR20230042055A (ko)	2020-07-20	2023-03-27	다이이찌 산쿄 가부시키가이샤	항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합
WO2022024024A2 (en)	2020-07-29	2022-02-03	Janssen Biotech, Inc.	Proteins comprising hla-g antigen binding domains and their uses
RU2764216C1 (ru) *	2020-08-10	2022-01-14	Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова"	Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
MX2023001776A (es)	2020-08-12	2023-03-10	Biond Biologics Ltd	Anticuerpos contra ilt2 y uso de los mismos.
AU2021334950A1 (en)	2020-08-24	2023-03-02	Charité - Universitätsmedizin Berlin	Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
AU2021334107A1 (en)	2020-08-24	2023-03-02	Charité - Universitätsmedizin Berlin	A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing CD44v6
US20230331867A1 (en)	2020-09-04	2023-10-19	Novarock Biotherapeutics, Ltd.	Nectin-4 antibodies and uses thereof
WO2022049273A1 (en)	2020-09-07	2022-03-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of treatment of inflammatory bowel diseases
WO2022054009A2 (en)	2020-09-12	2022-03-17	Astrazeneca Uk Limited	A scoring method for an anti-her2 antibody-drug conjugate therapy
IL301883A (en)	2020-10-05	2023-06-01	Chiome Bioscience Inc	Medicament for treating cancer
CN116348115A (zh)	2020-10-09	2023-06-27	阿斯利康(英国)有限公司	抗体-药物缀合物和parp1选择性抑制剂的组合
KR20230086765A (ko)	2020-10-13	2023-06-15	얀센 바이오테크 인코포레이티드	분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
US20230416346A1 (en)	2020-10-21	2023-12-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	C-terminal sparc fragments for treating cancer
AU2021363766A1 (en)	2020-10-22	2023-06-15	Janssen Biotech, Inc.	Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022097090A1 (en)	2020-11-05	2022-05-12	Novartis Ag	Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
CN116917502A (zh)	2020-11-06	2023-10-20	Inserm(法国国家健康医学研究院)	诊断和治疗多囊卵巢综合征（pcos）的方法
BR112023008845A2 (pt)	2020-11-11	2023-10-03	Daiichi Sankyo Co Ltd	Composição farmacêutica, e, método de tratamento
WO2022102695A1 (ja)	2020-11-12	2022-05-19	第一三共株式会社	抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療
US11897954B2 (en)	2020-11-16	2024-02-13	Astellas Pharma Inc.	Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody
US20240003879A1 (en)	2020-11-27	2024-01-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and monitoring of toxic epidermal necrolysis
TW202241436A (zh)	2020-11-30	2022-11-01	美商英塞特公司	抗ｃｄ１９抗體及帕薩昔布（ｐａｒｓａｃｌｉｓｉｂ）之組合療法
WO2022115120A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
EP4260872A4 (en)	2020-12-09	2024-11-13	National University Corporation Tokyo Medical and Dental University	AGENTS FOR PREVENTING OR TREATING FRONTOTEMPORAL LOBAR DEGENERATION
CA3207066A1 (en)	2020-12-29	2022-07-07	Incyte Corporation	Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022153212A1 (en)	2021-01-13	2022-07-21	Axon Neuroscience Se	Antibodies neutralizing sars-cov-2
US20240115720A1 (en)	2021-01-13	2024-04-11	Memorial Sloan Kettering Cancer Center	Antibody-pyrrolobenzodiazepine derivative conjugate
EP4277665A1 (en)	2021-01-13	2023-11-22	Memorial Sloan Kettering Cancer Center	Anti-dll3 antibody-drug conjugate
KR20230137393A (ko)	2021-01-28	2023-10-04	얀센 바이오테크 인코포레이티드	Psma 결합 단백질 및 이의 용도
WO2022162569A1 (en)	2021-01-29	2022-08-04	Novartis Ag	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202241454A (zh)	2021-02-01	2022-11-01	日商第一三共股份有限公司	抗體－免疫賦活化劑共軛物之新穎製造方法
MX2023009434A (es)	2021-02-11	2023-08-15	Nectin Therapeutics Ltd	Anticuerpos contra cd112r y usos de los mismos.
MX2023009484A (es)	2021-02-12	2023-11-09	Boehringer Ingelheim Int	Proteinas de union al antigeno complemento c3.
US12521444B2 (en)	2021-02-25	2026-01-13	Fortvita Biologics Limited	Anti-HER2 antibody-drug conjugates and uses thereof
EP4301777A1 (en)	2021-03-02	2024-01-10	Dana-Farber Cancer Institute, Inc.	Methods of treating red blood cell disorders
EP4306546A4 (en)	2021-03-12	2025-06-18	Daiichi Sankyo Company, Limited	GLYCAN AND METHOD FOR PRODUCING A Glycan-CONTAINING MEDICINAL PRODUCT
WO2022189632A1 (en)	2021-03-12	2022-09-15	Fibrosys S.R.L.	Monoclonal antibodies for the treatment of viral infections
CA3214259A1 (en)	2021-03-24	2022-09-29	Janssen Biotech, Inc.	Antibody targeting cd22 and cd79b
AU2022242125A1 (en)	2021-03-24	2023-11-09	Janssen Biotech, Inc.	Proteins comprising cd3 antigen binding domains and uses thereof
EP4314059A1 (en)	2021-03-26	2024-02-07	Janssen Biotech, Inc.	Humanized antibodies against paired helical filament tau and uses thereof
WO2022218998A1 (en)	2021-04-13	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for treating hepatitis b and d virus infection
KR20230170672A (ko)	2021-04-14	2023-12-19	빌라리스 테라퓨틱스 인코포레이티드	항-cd122 항체 및 이의 용도
PE20241357A1 (es)	2021-04-22	2024-07-03	Astellas Pharma Inc	Anticuerpo biespecifico anti-cldn4/anti-cd137
US20240280561A1 (en)	2021-06-08	2024-08-22	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN113361141B (zh) *	2021-07-11	2022-02-18	西南石油大学	一种dna图谱算法的改进试验方法
EP4392454A4 (en)	2021-08-27	2025-10-15	Janssen Biotech Inc	ANTI-PSMA ANTIBODIES AND THEIR USES
CN118317795A (zh)	2021-09-15	2024-07-09	第一三共株式会社	用在治疗化疗耐药性癌症的方法中的抗体-药物偶联物
US20240316061A1 (en)	2021-09-17	2024-09-26	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
US20250019455A1 (en)	2021-09-24	2025-01-16	Pharmaceutica Nv	Proteins comprising cd20 binding domains, and uses thereof
WO2023052541A1 (en)	2021-09-30	2023-04-06	Imcheck Therapeutics	Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
AU2022368385A1 (en)	2021-10-18	2024-04-11	Daiichi Sankyo Company, Limited	Anti-cd37 antibody-drug conjugate
JP2024539893A (ja)	2021-10-27	2024-10-31	イムチェックセラピューティクスエスエーエス	感染性障害を治療する方法で使用するためのブチロフィリン（ｂｔｎ）３ａ活性化抗体
EP4177266A1 (en)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
US20250025568A1 (en)	2021-11-18	2025-01-23	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and parp1 selective inhibitor
US20250019708A1 (en)	2021-11-19	2025-01-16	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
US20250381241A1 (en)	2021-11-29	2025-12-18	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
JP7235262B1 (ja)	2021-12-07	2023-03-08	国立大学法人大阪大学	抗体又はその抗原結合性断片
WO2023105528A1 (en)	2021-12-12	2023-06-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to ceacam1
IL313736A (en)	2021-12-22	2024-08-01	Incyte Corp	Treatment paradigm for CD19 antibody therapy
CN118434764A (zh)	2021-12-22	2024-08-02	Cdr生物科技股份有限公司	抗c3抗体及其抗原结合片段及其用于治疗眼疾病的用途
KR20240130087A (ko)	2021-12-28	2024-08-28	아스트라제네카 유케이 리미티드	항체-약물 접합체와 atr 저해제의 조합
CN118434422A (zh)	2021-12-28	2024-08-02	阿斯利康(英国)有限公司	抗体-药物缀合物和rasg12c抑制剂的组合
WO2023145844A1 (ja)	2022-01-27	2023-08-03	株式会社カイオム・バイオサイエンス	抗ヒトｃｘｃｌ１抗体
WO2023152581A1 (en)	2022-02-09	2023-08-17	Janssen Biotech, Inc.	Method of treating cancer with psmaxcd3 antibody
CN119233986A (zh)	2022-03-02	2024-12-31	海德堡免疫疗法有限公司	包含抗体或者包含含有抗体的Fc部分的含Fc融合蛋白的疫苗
EP4488378A1 (en)	2022-03-02	2025-01-08	Daiichi Sankyo Company, Limited	Method for producing fc-containing molecule
WO2023171009A1 (ja)	2022-03-09	2023-09-14	株式会社Cured	Ｅｖａ１タンパク質に結合する、ヒト化抗体又はその機能的断片、抗体薬物複合体及びキメラ抗原受容体
WO2023175614A1 (en)	2022-03-15	2023-09-21	Yeda Research And Development Co. Ltd.	Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
KR20240165390A (ko)	2022-03-16	2024-11-22	아스트라제네카 유케이 리미티드	항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
WO2023210405A1 (ja)	2022-04-25	2023-11-02	公益財団法人東京都医学総合研究所	変異型の神経変性疾患関連タンパク質
EP4514391A1 (en)	2022-04-27	2025-03-05	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023218378A1 (en)	2022-05-11	2023-11-16	Daiichi Sankyo Company, Limited	Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
US20250304706A1 (en)	2022-05-12	2025-10-02	Astellas Pharma Inc.	Anti-taa/anti-cd3 multispecific antibody
EP4531927A1 (en)	2022-05-24	2025-04-09	Daiichi Sankyo Company, Limited	Dosage regimen of an anti-cdh6 antibody-drug conjugate
CN119730880A (zh)	2022-06-07	2025-03-28	国立大学法人东京科学大学	肌萎缩侧索硬化症、帕金森病、亨廷顿病、脊髓小脑性共济失调、与老化有关的变性疾病或神经疾病、脑老化、或者伴有脑老化的疾病的预防剂或治疗剂
JP2025524727A (ja)	2022-07-15	2025-07-30	フィアンセラピューティクスエルティーディー	Ｃｄｃｐ１と結合する抗体薬物複合体及びその使用
US20250360222A1 (en)	2022-07-28	2025-11-27	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
KR20250054799A (ko)	2022-08-29	2025-04-23	다이이찌 산쿄 가부시키가이샤	변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
EP4585601A1 (en)	2022-09-09	2025-07-16	Daiichi Sankyo Company, Limited	Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide
WO2024072893A1 (en)	2022-09-28	2024-04-04	Incyte Corporation	Anti-pd-1/lag-3 bispecific antibodies and uses thereof
AU2023355736A1 (en)	2022-10-04	2025-03-27	Centre National De La Recherche Scientifique	Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
JP2025535258A (ja)	2022-10-19	2025-10-24	マルチチュードセラピューティクスインコーポレイテッド	抗体、抗体薬物複合体、これらの調製及び使用
WO2024083166A1 (zh)	2022-10-19	2024-04-25	普众发现医药科技(上海)有限公司	抗体-药物偶联物及其制备方法和在抗肿瘤中的用途
CN120456922A (zh)	2022-11-25	2025-08-08	国立大学法人大阪大学	针对血液癌的抗体
WO2024116094A1 (en)	2022-11-30	2024-06-06	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugates and dnmt inhibitors
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
CN120958025A (zh)	2022-12-16	2025-11-14	费恩治疗有限公司	针对含cub结构域的蛋白1(cdcp1)的抗体及其用途
IL321045A (en)	2022-12-22	2025-07-01	Chiome Bioscience Inc	Anti-human CX3CR1 antibody
WO2024158047A1 (ja)	2023-01-27	2024-08-02	第一三共株式会社	抗ｌｒｒｃ１５抗体
EP4665354A1 (en)	2023-02-13	2025-12-24	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of iron overload associated diseases
WO2024175699A1 (en)	2023-02-23	2024-08-29	Imcheck Therapeutics	Combination of btn3a activating antibody and immune checkpoint inhibitors
WO2024184476A1 (en)	2023-03-07	2024-09-12	Institut Curie	Ung/udg inhibition in brca-associated cancer
CN120813389A (zh)	2023-03-14	2025-10-17	第一三共株式会社	抗cdh6抗体-药物缀合物和vegf抑制剂的组合
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
IL320593A (en)	2023-03-29	2025-07-01	Daiichi Sankyo Co Ltd	Anti-CD25 antibody and anti-CD25 antibody conjugate
EP4691497A1 (en)	2023-03-31	2026-02-11	Daiichi Sankyo Company, Limited	Combination of anti-cdh6 antibody-drug conjugate and hif-2alpha inhibitor
TW202506190A (zh)	2023-04-05	2025-02-16	日商第一三共股份有限公司	利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
TW202446421A (zh)	2023-04-10	2024-12-01	日商第一三共股份有限公司	抗ｂ７－ｈ３抗體－藥物結合物與ａｔｒ抑制劑或ａｔｍ抑制劑之組合
EP4695290A1 (en)	2023-04-13	2026-02-18	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
EP4695294A1 (en)	2023-04-14	2026-02-18	Incyte Corporation	Use of an anti-tgfbetar2/pd-1 bispecific antibody to treat cancer
CN121335716A (zh)	2023-04-19	2026-01-13	第一三共株式会社	抗体-药物缀合物和其他药物的组合
TW202506731A (zh)	2023-04-27	2025-02-16	法商感應檢查療法公司	治療多重抗藥性細菌感染之方法
CN121219009A (zh)	2023-05-17	2025-12-26	信达克思制药公司	使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法
WO2024248123A1 (ja)	2023-06-02	2024-12-05	第一三共株式会社	抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ
CN119143869A (zh)	2023-06-16	2024-12-17	复旦大学	乙肝病毒表面抗体及其应用
WO2025003461A1 (en)	2023-06-30	2025-01-02	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of metabolic disorders
WO2025005240A1 (ja)	2023-06-30	2025-01-02	第一三共株式会社	活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025024272A1 (en)	2023-07-23	2025-01-30	Incyte Corporation	Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
WO2025034542A1 (en)	2023-08-04	2025-02-13	Cornell University	Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
US20250136688A1 (en)	2023-08-07	2025-05-01	Janssen Biotech, Inc.	Stabilized cd3 antigen binding agents and methods of use thereof
WO2025040820A1 (en)	2023-08-23	2025-02-27	Granular Therapeutics Limited	Anti-cd203c antibody conjugates and uses thereof
WO2025056739A1 (en)	2023-09-14	2025-03-20	Medizinische Universität Innsbruck	Enhancement of car-t cell efficacy by inhibiting nr2f6
WO2025068180A1 (en)	2023-09-25	2025-04-03	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025068157A1 (en)	2023-09-25	2025-04-03	Stromacare	COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025068393A1 (en)	2023-09-27	2025-04-03	Institut Curie	Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma
WO2025088496A1 (en)	2023-10-24	2025-05-01	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
EP4563586A1 (en)	2023-11-28	2025-06-04	Université Paris Cité	New inhibitors of lrrk2/pp1 interaction
WO2025120513A1 (en)	2023-12-05	2025-06-12	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
US20250186450A1 (en)	2023-12-06	2025-06-12	Incyte Corporation	COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
EP4570262A1 (en)	2023-12-15	2025-06-18	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Chimeric antigen receptor directed against the chemokine receptor ccr7
WO2025147576A1 (en)	2024-01-06	2025-07-10	Generate Biomedicines, Inc.	Anti-il-13 antibodies and methods of use thereof
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025176777A1 (en)	2024-02-20	2025-08-28	Institut Curie	Dut inhibition in homologous recombination deficiency cancer
WO2025176860A1 (en)	2024-02-23	2025-08-28	Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts	Dual chimeric antigen receptor construct targeting cea and epcam
FR3159967A1 (fr)	2024-03-06	2025-09-12	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Anticorps neutralisant à haute affinité dirigé contre la ricine
WO2025215252A1 (en)	2024-04-12	2025-10-16	Ensocell Ltd	Therapeutic agents and methods for targeting myeloid cell subtypes
EP4635980A1 (en)	2024-04-19	2025-10-22	Medigene Immunotherapies GmbH	Uni-tags specific antibody
US20250325664A1 (en)	2024-04-22	2025-10-23	Incyte Corporation	Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
WO2025224050A1 (en)	2024-04-22	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of patients suffering from hypomelanosis of ito
WO2025262641A1 (en)	2024-06-19	2025-12-26	Pheon Therapeutics Ltd	Antibody drug conjugates that bind cdcp1 and uses thereof
EP4674430A1 (en)	2024-07-01	2026-01-07	Universität zu Köln	Edited cytotoxic cells with chimeric antigen receptors targeting cd30 for the treatment of infections
WO2026013153A1 (en)	2024-07-10	2026-01-15	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from myc-high tumors
WO2026020031A2 (en)	2024-07-18	2026-01-22	Novarock Biotherapeutics, Ltd.	Cdh17 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
JPS6033453B2 (ja) *	1978-08-17	1985-08-02	富士電機株式会社	魚切断加工自動化装置
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6014678A (ja) *	1983-07-04	1985-01-25	Taiheiyo Kogyo Kk	電磁弁
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB2188941B (en) *	1986-04-14	1990-06-06	Bayer Ag	Monoclonal antibodies recognizing human interleukin-2-receptor
DK554986A (da) *	1986-11-19	1988-07-18	Novo Industri As	Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer
GB8720833D0 (en) *	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
ES2059719T3 (es) *	1988-02-12	1994-11-16	British Tech Group	Mejoras relativas a anticuerpos.
AU631545B2 (en) *	1988-04-15	1992-12-03	Protein Design Labs, Inc.	Il-2 receptor-specific chimeric antibodies
JP5598363B2 (ja)	2011-02-15	2014-10-01	ソニー株式会社	記憶装置およびその動作方法

1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 EP EP95105609A patent/EP0682040B1/en not_active Revoked
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 EP EP90903576A patent/EP0451216B9/en not_active Expired - Lifetime
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/en not_active Expired - Lifetime
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 MC MC@@@@D patent/MC2146A1/xx unknown
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/en not_active Expired - Lifetime
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active Expired - Lifetime
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 EP EP10185689A patent/EP2341080A1/en not_active Withdrawn
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/en not_active Expired - Lifetime
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/en not_active Ceased
- 1989-12-28 CA CA002006865A patent/CA2006865C/en not_active Expired - Lifetime
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
- 1989-12-28 CA CA002328851A patent/CA2328851C/en not_active Expired - Lifetime
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
1990
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-06-19 DK DK119191A patent/DK119191A/da not_active Application Discontinuation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
1992
- 1992-01-20 BG BG095784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
2000
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
2001
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
2003
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
2006
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active

Also Published As

Publication number	Publication date
EP0682040B1 (en)	1999-08-25
FI912436A0 (fi)	1991-05-20
NL300213I2 (nl)	2006-07-03
DE68925536T4 (de)	1996-09-19
EP0451216A4 (en)	1992-01-02
BG61095B2 (en)	1996-10-31
IL162181A (en)	2006-04-10
IL162181A0 (en)	2005-11-20
DK119191D0 (da)	1991-06-19
NL300023I2 (nl)	2001-09-03
DE19975047I2 (de)	2008-07-03
EP0451216B9 (en)	2012-09-26
JPH114694A (ja)	1999-01-12
ATE183753T1 (de)	1999-09-15
JP2003245090A (ja)	2003-09-02
NL300426I1 (nl)	2010-02-01
DE10075038I2 (de)	2004-08-12
NO2005026I1 (no)	2005-12-27
FI108797B (fi)	2002-03-28
DK119191A (da)	1991-06-19
LU91139I2 (fr)	2005-04-04
JPH04502408A (ja)	1992-05-07
NO2001025I2 (no)	2005-03-21
LU91208I2 (fr)	2006-02-28
HU211174A9 (en)	1995-11-28
LU90528I2 (fr)	2000-04-11
DK199800941A (da)	1998-07-16
LU91333I2 (fr)	2007-06-11
HK1014718A1 (en)	1999-09-30
IL92904A0 (en)	1990-09-17
MC2146A1 (fr)	1992-02-18
EP0451216A1 (en)	1991-10-16
SI8912489A (sl)	1999-02-28
DE68929061D1 (de)	1999-09-30
DE122005000057I2 (de)	2009-07-16
AU5153290A (en)	1990-08-13
PT92758A (pt)	1990-06-29
HRP920500A2 (en)	1996-04-30
NL990020I2 (nl)	1999-11-01
LU91627I2 (fr)	2010-02-09
NL300239I2 (nl)	2007-03-01
SI8912489B (sl)	2000-04-30
ES2523810T3 (es)	2015-01-12
DE68925536T2 (de)	1996-06-20
NL300213I1 (nl)	2006-02-01
CZ418691A3 (en)	1993-10-13
EP2341080A1 (en)	2011-07-06
DE68925536T3 (de)	2012-11-22
CN1043875A (zh)	1990-07-18
YU48700B (sh)	1999-07-28
NL300173I2 (nl)	2006-05-01
CA2328851A1 (en)	1990-06-28
NL300279I2 (nl)	2007-10-01
NO2005026I2 (no)	2009-01-19
DE122009000071I1 (de)	2010-03-25
EP0939127A3 (en)	2004-07-21
YU248989A (en)	1991-10-31
ES2081974T5 (es)	2012-10-29
NL300173I1 (nl)	2005-04-01
NL990020I1 (nl)	1999-09-01
CA2006865C (en)	2002-08-20
CA2328851C (en)	2002-08-13
DE68929061T2 (de)	2000-04-27
DE98204240T1 (de)	2014-08-21
DE10075005I1 (de)	2000-11-23
RU2126046C1 (ru)	1999-02-10
JP2007145863A (ja)	2007-06-14
DE122005000007I2 (de)	2009-06-25
LU91272I2 (fr)	2006-10-09
IE20000331A1 (en)	2001-02-21
EP1491556B1 (en)	2014-04-30
ES2136760T3 (es)	1999-12-01
FR14C0070I1 (fr)	2014-10-24
NL300023I1 (nl)	2001-01-02
NZ231984A (en)	1997-06-24
EP0451216B2 (en)	2012-06-13
NO912385L (no)	1991-06-19
DE04076439T1 (de)	2014-12-18
NO912385D0 (no)	1991-06-19
DE122006000036I1 (de)	2007-04-19
KR0178385B1 (ko)	1999-04-01
NZ314793A (en)	1999-11-29
HRP920500B1 (en)	1999-12-31
EP1491556A1 (en)	2004-12-29
EP0451216B1 (en)	1996-01-24
DE122007000037I1 (de)	2007-08-02
DE68925536D1 (de)	1996-03-07
NL300239I1 (nl)	2006-10-02
SG78258A1 (en)	2001-02-20
NO2007006I2 (no)	2009-12-07
DK174317B1 (da)	2002-12-02
NL300279I1 (nl)	2007-07-02
ES2492815T1 (es)	2014-09-10
CA2006865A1 (en)	1990-06-28
NO2001026I2 (no)	2006-11-20
LU90676I2 (fr)	2001-02-05
ES2492815T3 (es)	2014-10-08
ES2440825T1 (es)	2014-01-30
NO2006009I1 (no)	2006-08-07
DE122005000057I1 (de)	2009-04-09
EP0939127B1 (en)	2014-09-17
NO2001024I1 (no)	2002-01-21
NO2007006I1 (no)	2007-05-07
PT92758B (pt)	1996-01-31
NO2009026I1 (no)	2009-11-30
DE122005000007I1 (de)	2005-06-30
WO1990007861A1 (en)	1990-07-26
NL300005I1 (nl)	2000-04-03
JP2009165488A (ja)	2009-07-30
DD296964A5 (de)	1991-12-19
DE10075038I1 (de)	2001-03-01
JP3604058B2 (ja)	2004-12-22
JP2003245091A (ja)	2003-09-02
JP2828340B2 (ja)	1998-11-25
ES2523810T1 (es)	2014-12-01
ATE133452T1 (de)	1996-02-15
DE04076438T1 (de)	2014-02-27
AU647383B2 (en)	1994-03-24
NL300005I2 (nl)	2000-10-02
NO2006009I2 (no)	2009-12-07
ZA899956B (en)	1990-10-31
ES2440825T3 (es)	2014-05-19
EP0682040A1 (en)	1995-11-15
EP1477497B1 (en)	2014-11-26
LU90411I2 (fr)	1999-09-02
NO2005005I2 (no)	2009-01-19
KR910700350A (ko)	1991-03-14
CN1057013C (zh)	2000-10-04
EP0939127A2 (en)	1999-09-01
EP1477497A1 (en)	2004-11-17
ES2081974T3 (es)	1996-03-16
DE10075005I2 (de)	2005-06-23

Publication	Publication Date	Title
NO310473B1 (no)	2001-07-09	Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid
US5585089A (en)	1996-12-17	Humanized immunoglobulins
US20080160018A1 (en)	2008-07-03	Humanized immunoglobulins
HK1014718B (en)	2000-07-14	Production of humanized immunoglobulins and corresponding polynucleotiodies

Legal Events

Date	Code	Title	Description
2003-12-29	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: TRASTUZUMAB ELLER FARMASOEYTISKE AKSEPTABLE SALTER DERAV; NAT. REG. NO/DATE: NO , EU/1/00/14 20000928; FIRST REG. NO/DATE: EP , EU/1/00/14 20000828 Spc suppl protection certif: 2001024 Filing date: 20011217 Extension date: 20141228 Effective date: 20031229
2005-12-27	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: XOLAIR, 75 MG OG 150 MG, PULVER OG VAESKE TIL INJEKSJONSVAESKE, OPPLOESNING; NAT. REG. NO/DATE: EU/1/05/319/00-002/NO 20051025; FIRST REG. NO/DATE: EU , EU/1/05/319/00-002 20051025 Spc suppl protection certif: 2005026 Filing date: 20051207 Extension date: 20141228
2006-08-21	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: TYSABRI; NAT. REG. NO/DATE: EU106346NO 20060627; FIRST REG. NO/DATE: EU , EU106346 20060627 Spc suppl protection certif: 2006009 Filing date: 20060807 Extension date: 20141228
2006-11-20	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: DACLIZUMAB; NAT. REG. NO/DATE: NO , 97-3585 19991126; FIRST REG. NO/DATE: EP , EU/1/99/09 19990226 Spc suppl protection certif: 2001026 Filing date: 20011217 Extension date: 20130303
2007-05-07	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: LUCENTIS 10 MG/ML INJEKSJONSVAESKE, OPPLOSNING "NOVARTIS EUROPHARM" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU106374001NO 20070207; FIRST REG. NO/DATE: LI , 57664 20060825 Spc suppl protection certif: 2007006 Filing date: 20070418 Extension date: 20141228
2009-01-19	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: AVASTIN, 25 MG/ML, KONSENTRAT TIL OPPLOSNING FOR INFUSJON, INTRAVENOS ANVENDELSE; NAT. REG. NO/DATE: EU/1/04/300/001/NO-002/NO 20050118; FIRST REG. NO/DATE: EU , EU/1/04/300/001-002 20050112 Spc suppl protection certif: 2005005 Filing date: 20050218 Extension date: 20141228 Free format text: PRODUCT NAME: XOLAIR, 75 MG OG 150 MG, PULVER OG VAESKE TIL INJEKSJONSVAESKE, OPPLOESNING; NAT. REG. NO/DATE: EU/1/05/319/00-002/NO 20051025; FIRST REG. NO/DATE: EU , EU/1/05/319/00-002 20051025 Spc suppl protection certif: 2005026 Filing date: 20051207 Extension date: 20141228
2009-12-07	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: LUCENTIS 10 MG/ML INJEKSJONSVAESKE, OPPLOSNING "NOVARTIS EUROPHARM" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU106374001NO 20070207; FIRST REG. NO/DATE: LI , 57664 20060825 Spc suppl protection certif: 2007006 Filing date: 20070418 Extension date: 20141228 Free format text: PRODUCT NAME: TYSABRI; NAT. REG. NO/DATE: EU106346NO 20060627; FIRST REG. NO/DATE: EU , EU106346 20060627 Spc suppl protection certif: 2006009 Filing date: 20060807 Extension date: 20141228
2010-01-18	MK1K	Patent expired
2015-01-12	SPCX	Expiry of an spc	Spc suppl protection certif: 2005005 Effective date: 20141228 Spc suppl protection certif: 2001024 Effective date: 20141228 Spc suppl protection certif: 2006009 Effective date: 20141228 Spc suppl protection certif: 2007006 Effective date: 20141228 Spc suppl protection certif: 2005026 Effective date: 20141228